<!DOCTYPE html>
<html lang="en">
<head>
<meta name="robots" content="noindex, nofollow">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1">
<title>Paper — When Courts Allocate</title>
<style>
  :root {
    --bg: #f8f9fa; --card: #fff; --fg: #1a1a1a; --muted: #666;
    --border: #dee2e6; --accent: #0d6efd; --accent2: #198754;
  }
  * { box-sizing: border-box; margin: 0; padding: 0; }
  body {
    font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, sans-serif;
    background: var(--bg); color: var(--fg); line-height: 1.5;
  }

  main {
    padding: 1.5rem 2rem 3rem; max-width: 1000px; margin: 0 auto;
  }

  .paper-body { line-height: 1.7; color: #1f2328; }
  .paper-body img { max-width: 100%; }

  footer {
    text-align: center; padding: 1.5rem; font-size: .8rem; color: var(--muted);
    border-top: 1px solid var(--border); margin-top: 2rem;
  }
</style>
<style>
/* make4ht styles */
 
/* start css.sty */
.cmr-10{font-size:83%;}
.cmmi-7{font-size:58%;font-style: italic;}
.cmmi-10{font-size:83%;font-style: italic;}
.cmsy-10{font-size:83%;}
.ecrm-2074{font-size:166%;}
.ecrm-1440{font-size:116%;}
.tcrm-1440{font-size:116%;}
.ecrm-1095{font-size:83%;}
.ecbx-1095{font-size:83%; font-weight: bold;}
.ecbx-1095{ font-weight: bold;}
.ecbx-1095{ font-weight: bold;}
.ecbx-1095{ font-weight: bold;}
.ecbx-1095{ font-weight: bold;}
.ecbx-1095{ font-weight: bold;}
.ecbx-1095{ font-weight: bold;}
.ecbx-1095{ font-weight: bold;}
.ecbx-1095{ font-weight: bold;}
.ecbx-1200{ font-weight: bold;}
.ecbx-1200{ font-weight: bold;}
.ecbx-1200{ font-weight: bold;}
.ecbx-1200{ font-weight: bold;}
.ecbx-1200{ font-weight: bold;}
.ecbx-1200{ font-weight: bold;}
.ecbx-1200{ font-weight: bold;}
.ecbx-1200{ font-weight: bold;}
.ecbx-1200{ font-weight: bold;}
.ecti-1200{ font-style: italic;}
.ecti-1200{ font-style: italic;}
.ecti-1200{ font-style: italic;}
.ecti-1200{ font-style: italic;}
.ecti-1200{ font-style: italic;}
.ecti-1200{ font-style: italic;}
.ecti-1200{ font-style: italic;}
.ecti-1200{ font-style: italic;}
.ecti-1200{ font-style: italic;}
.ecrm-1000{font-size:83%;}
.ecti-1000{font-size:83%; font-style: italic;}
.ecti-1000{ font-style: italic;}
.ecti-1000{ font-style: italic;}
.ecti-1000{ font-style: italic;}
.ecti-1000{ font-style: italic;}
.ecti-1000{ font-style: italic;}
.ecti-1000{ font-style: italic;}
.ecti-1000{ font-style: italic;}
.ecti-1000{ font-style: italic;}
.cmr-8{font-size:66%;}
.cmmi-12{font-style: italic;}
.cmmi-8{font-size:66%;font-style: italic;}
.cmsy-8{font-size:66%;}
p{margin-top:0;margin-bottom:0}
p.indent{text-indent:0;}
p + p{margin-top:1em;}
p + div, p + pre {margin-top:1em;}
div + p, pre + p {margin-top:1em;}
a { overflow-wrap: break-word; word-wrap: break-word; word-break: break-word; hyphens: auto; }
@media print {div.crosslinks {visibility:hidden;}}
table.tabular{border-collapse: collapse; border-spacing: 0;}
a img { border-top: 0; border-left: 0; border-right: 0; }
center { margin-top:1em; margin-bottom:1em; }
td center { margin-top:0em; margin-bottom:0em; }
.Canvas { position:relative; }
img.math{vertical-align:middle;}
div.par-math-display, div.math-display{text-align:center;}
li p.indent { text-indent: 0em }
li p:first-child{ margin-top:0em; }
li p:last-child, li div:last-child { margin-bottom:0.5em; }
li p:first-child{ margin-bottom:0; }
li p~ul:last-child, li p~ol:last-child{ margin-bottom:0.5em; }
.enumerate1 {list-style-type:decimal;}
.enumerate2 {list-style-type:lower-alpha;}
.enumerate3 {list-style-type:lower-roman;}
.enumerate4 {list-style-type:upper-alpha;}
div.newtheorem { margin-bottom: 2em; margin-top: 2em;}
div.newtheorem .head{font-weight: bold;}
.obeylines-h,.obeylines-v {white-space: nowrap; }
div.obeylines-v p { margin-top:0; margin-bottom:0; }
.overline{ text-decoration:overline; }
.overline img{ border-top: 1px solid black; }
td.displaylines {text-align:center; white-space:nowrap;}
.centerline {text-align:center;}
.rightline {text-align:right;}
pre.verbatim {font-family: monospace,monospace; text-align:left; clear:both; }
.fbox {padding-left:3.0pt; padding-right:3.0pt; text-indent:0pt; border:solid black 0.4pt; }
div.fbox {display:table}
div.center div.fbox {text-align:center; clear:both; padding-left:3.0pt; padding-right:3.0pt; text-indent:0pt; border:solid black 0.4pt; }
div.minipage{width:100%;}
div.center, div.center div.center {text-align: center; margin-left:1em; margin-right:1em;}
div.center div {text-align: left;}
div.flushright, div.flushright div.flushright {text-align: right;}
div.flushright div {text-align: left;}
div.flushleft {text-align: left;}
.underline{ text-decoration:underline; }
.underline img{ border-bottom: 1px solid black; margin-bottom:1pt; }
.framebox-c, .framebox-l, .framebox-r { padding-left:3.0pt; padding-right:3.0pt; text-indent:0pt; border:solid black 0.4pt; }
.framebox-c {text-align:center;}
.framebox-l {text-align:left;}
.framebox-r {text-align:right;}
span.thank-mark{ vertical-align: super }
span.footnote-mark sup.textsuperscript, span.footnote-mark a sup.textsuperscript{ font-size:80%; }
div.tabular, div.center div.tabular {text-align: center; margin-top:0.5em; margin-bottom:0.5em; }
table.tabular td p{margin-top:0em;}
table.tabular {margin-left: auto; margin-right: auto;}
td p:first-child{ margin-top:0em; }
td p:last-child{ margin-bottom:0em; }
div.td00{ margin-left:0pt; margin-right:0pt; }
div.td01{ margin-left:0pt; margin-right:5pt; }
div.td10{ margin-left:5pt; margin-right:0pt; }
div.td11{ margin-left:5pt; margin-right:5pt; }
table[rules] {border-left:solid black 0.4pt; border-right:solid black 0.4pt; }
td.td00{ padding-left:0pt; padding-right:0pt; }
td.td01{ padding-left:0pt; padding-right:5pt; }
td.td10{ padding-left:5pt; padding-right:0pt; }
td.td11{ padding-left:5pt; padding-right:5pt; }
table[rules] {border-left:solid black 0.4pt; border-right:solid black 0.4pt; }
.hline hr, .cline hr{ height : 0px; margin:0px; }
.hline td, .cline td{ padding: 0; }
.hline hr, .cline hr{border:none;border-top:1px solid black;}
.hline {border-top: 1px solid black;}
.tabbing-right {text-align:right;}
div.float, div.figure {margin-left: auto; margin-right: auto;}
div.float img {text-align:center;}
div.figure img {text-align:center;}
.marginpar,.reversemarginpar {width:20%; float:right; text-align:left; margin-left:auto; margin-top:0.5em; font-size:85%; text-decoration:underline;}
.marginpar p,.reversemarginpar p{margin-top:0.4em; margin-bottom:0.4em;}
.reversemarginpar{float:left;}
table.equation {width:100%;}
.equation td{text-align:center; }
td.equation { margin-top:1em; margin-bottom:1em; } 
td.equation-label { width:5%; text-align:center; }
td.eqnarray4 { width:5%; white-space: normal; }
td.eqnarray2 { width:5%; }
table.eqnarray-star, table.eqnarray {width:100%;}
div.eqnarray{text-align:center;}
div.array {text-align:center;}
div.pmatrix {text-align:center;}
table.pmatrix {width:100%;}
span.pmatrix img{vertical-align:middle;}
div.pmatrix {text-align:center;}
table.pmatrix {width:100%;}
span.bar-css {text-decoration:overline;}
img.cdots{vertical-align:middle;}
.partToc a, .partToc, .likepartToc a, .likepartToc {line-height: 200%; font-weight:bold; font-size:110%;}
.chapterToc a, .chapterToc, .likechapterToc a, .likechapterToc, .appendixToc a, .appendixToc {line-height: 200%; font-weight:bold;}
.index-item, .index-subitem, .index-subsubitem {display:block}
div.caption {text-indent:-2em; margin-left:3em; margin-right:1em; text-align:left;}
div.caption span.id{font-weight: bold; white-space: nowrap; }
h1.partHead{text-align: center}
p.bibitem { text-indent: -2em; margin-left: 2em; margin-top:0.6em; margin-bottom:0.6em; }
p.bibitem-p { text-indent: 0em; margin-left: 2em; margin-top:0.6em; margin-bottom:0.6em; }
.paragraphHead, .likeparagraphHead { margin-top:2em; font-weight: bold;}
.subparagraphHead, .likesubparagraphHead { font-weight: bold;}
.verse{white-space:nowrap; margin-left:2em}
div.maketitle {text-align:center;}
h2.titleHead{text-align:center;}
div.maketitle{ margin-bottom: 2em; }
div.author, div.date {text-align:center;}
div.thanks{text-align:left; margin-left:10%; font-size:85%; font-style:italic; }
div.author{white-space: nowrap;}
div.abstract p {margin-left:5%; margin-right:5%;}
div.abstract {width:100%;}
.abstracttitle{text-align:center;margin-bottom:1em;}
figure.float, div.figure {margin-left: auto; margin-right: auto;}
figure.figure {text-align:center;}
figcaption.caption {text-indent:-2em; margin-left:3em; margin-right:1em; text-align:center;}
figcaption.caption span.id{font-weight: bold; white-space: nowrap; }
p + figcaption, img + figcaption{margin-top: 1em;}
.abstract{margin:1em;}
.equation td{text-align:center; }
.equation-star td{text-align:center; }
table.equation-star { width:100%; }
table.equation { width:100%; }
table.align, table.alignat, table.xalignat, table.xxalignat, table.flalign {width:95%; margin-left:5%; white-space: nowrap;}
table.align-star, table.alignat-star, table.xalignat-star, table.flalign-star {margin-left:auto; margin-right:auto; white-space: nowrap;}
td.align-label { width:5%; text-align:center; }
td.align-odd { text-align:right; padding-right:0.3em;}
td.align-even { text-align:left; padding-right:0.6em;}
table.multline, table.multline-star {width:100%;}
td.gather {text-align:center; }
table.gather {width:100%;}
div.gather-star {text-align:center;}
.rotatebox{display: inline-block;}
dt.printshorthands{float:left; clear:left; margin-right:1em;}
/* end css.sty */


</style>
</head>
<body>

<style>
  .site-nav {
    position: sticky; top: 0; z-index: 100;
    background: #212529; display: flex; align-items: center;
    padding: 0 2rem; height: 3rem;
  }
  .site-nav .nav-brand {
    color: #fff; text-decoration: none; font-weight: 600; font-size: 1rem;
    margin-right: auto;
  }
  .site-nav .nav-brand:hover { color: #e9ecef; }
  .site-nav .nav-link {
    color: #adb5bd; text-decoration: none; font-size: .85rem;
    padding: 0 .75rem; height: 3rem; display: flex; align-items: center;
    background: none; border: none; cursor: pointer; font-family: inherit;
  }
  .site-nav .nav-link:hover, .site-nav .nav-link.active { color: #fff; }
  .nav-dropdown { position: relative; }
  .dropdown-menu {
    display: none; position: absolute; top: 3rem; right: 0;
    background: #fff; border: 1px solid var(--border); border-radius: 6px;
    box-shadow: 0 4px 16px rgba(0,0,0,.12); min-width: 220px;
    padding: .4rem 0; z-index: 200; max-height: 80vh; overflow-y: auto;
  }
  .nav-dropdown.open .dropdown-menu { display: block; }
  .dropdown-menu a {
    display: block; padding: .3rem 1rem; color: #1a1a1a;
    text-decoration: none; font-size: .82rem;
  }
  .dropdown-menu a:hover { background: #f0f4f8; }
  .dropdown-group-label {
    padding: .4rem 1rem .15rem; font-size: .68rem; font-weight: 700;
    color: #888; text-transform: uppercase; letter-spacing: .04em;
  }
  .dropdown-divider { border-top: 1px solid #eee; margin: .3rem 0; }
  .page-header {
    padding: .8rem 2rem; border-bottom: 1px solid var(--border); background: #fff;
  }
  .page-header h1 { font-size: 1.3rem; font-weight: 600; }
  .page-header p { color: var(--muted); font-size: .85rem; margin-top: .15rem; }
</style>

<nav class="site-nav">
  <a href="../index.html" class="nav-brand">Judicialização da Saúde</a>
  <a href="../paper/index.html" class="nav-link active">Paper</a>
  <div class="nav-dropdown">
    <button class="nav-link">Docs &#9662;</button>
    <div class="dropdown-menu">
    <div class="dropdown-group-label">Research reference</div>
    <a href="../docs/README.html">Project Overview</a>
    <a href="../docs/summary.html">Research Summary</a>
    <a href="../docs/institutions.html">Institutional Background</a>
    <a href="../docs/data.html">Data Sources</a>
    <a href="../docs/methods.html">Empirical Methods</a>
    <a href="../docs/literature.html">Literature</a>
    <a href="../docs/theory.html">Theoretical Framework</a>
    <a href="../docs/hypotheses.html">Hypotheses & Evidence</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Working notes</div>
    <a href="../docs/thinking.html">Open Questions & Ideas</a>
    <a href="../docs/decisions.html">Key Decisions</a>
    <a href="../docs/qa.html">Research Q&A</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Task tracking</div>
    <a href="../docs/todo.html">Active Tasks</a>
    <a href="../docs/done.html">Completed Tasks</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Communication</div>
    <a href="../docs/meetings.html">Meeting Notes</a>
    <a href="../docs/feedback.html">External Feedback</a>
    <div class="dropdown-divider"></div>
    <div class="dropdown-group-label">Court analysis</div>
    <a href="../docs/01-stf-reasoning-templates.html">STF Reasoning Templates</a>
    <a href="../docs/02-stj-repetitivos-patterns.html">STJ Repetitivos Patterns</a>
    <a href="../docs/03-tjsp-plans-vs-sus.html">TJSP: Plans vs SUS</a>
    <a href="../docs/04-conitec-pcdt-vs-courts.html">CONITEC vs Courts</a>
    <a href="../docs/05-interfederative-responsibility.html">Interfederative Responsibility</a>
    </div>
  </div>
  <div class="nav-dropdown">
    <button class="nav-link">Data &#9662;</button>
    <div class="dropdown-menu">
    <a href="../sources/tjsp.html">TJSP</a>
    <a href="../sources/datajud.html">DataJud</a>
    <a href="../sources/stf-stj.html">STF & STJ</a>
    <a href="../sources/trf3.html">TRF3</a>
    <a href="../sources/spending.html">Municipal Spending</a>
    <a href="../sources/legislation.html">Health Legislation</a>
    </div>
  </div>
  <a href="../references/index.html" class="nav-link">References</a>
  <a href="../news/index.html" class="nav-link">News</a>
</nav>
<script>
document.querySelectorAll('.nav-dropdown > .nav-link').forEach(function(btn) {
  btn.addEventListener('click', function(e) {
    e.stopPropagation();
    var dd = btn.parentElement;
    var wasOpen = dd.classList.contains('open');
    document.querySelectorAll('.nav-dropdown.open').forEach(function(d) { d.classList.remove('open'); });
    if (!wasOpen) dd.classList.add('open');
  });
});
document.addEventListener('click', function() {
  document.querySelectorAll('.nav-dropdown.open').forEach(function(d) { d.classList.remove('open'); });
});
</script>

<div class="page-header">
  <h1>When Courts Allocate</h1>
  <p>Judicial Mandates, Budget Composition, and Health
    <a href="main.pdf" download style="margin-left:1rem;font-size:.82rem;font-weight:600;color:#0d6efd;text-decoration:none;">Download PDF &darr;</a>
  </p>
</div>

<main>
<div class="paper-body">
<div class='maketitle'>
                                                                          

                                                                          
                                                                          

                                                                          

<h2 class='titleHead'>When Courts Allocate:<br />
Judicial Mandates, Budget Composition, and
Health</h2>
<div class='author'><span class='ecrm-1440'>Daniela Soto</span><span class='thank-mark'><a href='#tk-1'><span class='tcrm-1440'>∗</span></a></span> <br class='and' /><span class='ecrm-1440'>Henrik Sigstad</span><span class='thank-mark'><a href='#tk-2'><span class='tcrm-1440'>†</span></a></span></div><br />
<div class='date'><span class='ecrm-1440'>February 10, 2026</span></div>
   <div class='thanks'><br /><a id='tk-1'></a><span class='thank-mark'><span class='tcrm-1200'>∗</span></span>BI Norwegian Business School<br /><a id='tk-2'></a><span class='thank-mark'><span class='tcrm-1200'>†</span></span>BI Norwegian Business School</div></div>
   <section class='abstract' role='doc-abstract'> 
<h3 class='abstracttitle'>
<span class='ecbx-1095'>Abstract</span>
</h3>
      <!-- l. 29 --><p class='noindent'><span class='ecrm-1095'>When courts mandate public spending, they override administrative
      </span><span class='ecrm-1095'>priority-setting  and  may  change  the  marginal  returns  to  public
      </span><span class='ecrm-1095'>resources.  This  logic  applies  whenever  external  authorities  impose
      </span><span class='ecrm-1095'>spending  obligations  on  local  budgets.  In  Brazil,  court  orders
      </span><span class='ecrm-1095'>directing municipalities to provide medicines and treatments absorb
      </span><span class='ecrm-1095'>a  substantial  share  of  local  health  budgets,  creating  a  large-scale
      </span><span class='ecrm-1095'>reallocation  from  programmatic  to  individualized  spending.  We
      </span><span class='ecrm-1095'>exploit  line-item  municipal  budget  records  that  directly  identify
      </span><span class='ecrm-1095'>court-mandated expenditures through judicial-compliance descriptors
      </span><span class='ecrm-1095'>in the transaction history field, revealing both the volume of judicial
      </span><span class='ecrm-1095'>spending  and  the  budget  categories  it  displaces.  Combining  these
      </span><span class='ecrm-1095'>data with the administrative universe of health case records, we use
      </span><span class='ecrm-1095'>the random assignment of judges to health lawsuits as a source of
      </span><span class='ecrm-1095'>exogenous variation in court-mandated spending at the municipality
                                                                          

                                                                          
      </span><span class='ecrm-1095'>level.  We  estimate  the  causal  effect  on  the  composition  of  health
      </span><span class='ecrm-1095'>budgets, population health outcomes, and the distributional incidence
      </span><span class='ecrm-1095'>across socioeconomic groups.</span>
</p>
</section>
<!-- l. 33 --><p class='noindent'><span class='ecbx-1200'>JEL Codes: </span>H75, I18, K41, H72, D63
</p><!-- l. 35 --><p class='noindent'><span class='ecbx-1200'>Keywords: </span>health judicialization, court mandates, public health spending, judge
leniency, instrumental variables, Brazil
</p>
   <h3 class='sectionHead' id='introduction'><span class='titlemark'>1   </span> <a id='x1-10001'></a>Introduction</h3>
<!-- l. 41 --><p class='noindent'>Public spending can be allocated administratively—through budgets, formularies,
and technology assessment—or by courts enforcing individual claims. The
institution that allocates may change the marginal returns. In Brazil, courts now
direct billions of reais in public health spending toward individual litigants:
in 2024, the federal government spent R$1.9 billion on court-mandated
pharmaceutical assistance alone (<a id='x1-1001'></a>Instituto de Pesquisa Econômica Aplicada,
<a href='#cite.0@ipea2025'>2025</a>), with total Ministry of Health judicial compliance costs reaching
R$2.7 billion (<a id='x1-1002'></a>Folha de S.Paulo, <a href='#cite.0@folha2025elevidys'>2025b</a>)—an amount equivalent to the
entire budget of Farmácia Popular, the country’s flagship pharmaceutical
assistance program. In the same year, over 270 municipalities devoted
between 30 and 100 percent of their health budgets to fulfilling judicial
mandates, while primary care facilities in those same municipalities reported
shortages of basic supplies and routine medications (<a id='x1-1003'></a>Brito, <a href='#cite.0@theconversation2024'>2024</a>). The
resources courts command are drawn from the same budget that finances
population-level health programs. Whether this reallocation improves or worsens
                                                                          

                                                                          
population health depends on the relative marginal returns to court-mandated
and administratively allocated spending—a question that has remained
unanswered for lack of credible identification and direct measurement of the
mechanism.
</p><!-- l. 43 --><p class='indent'>   This paper estimates the causal effect of court-mandated health spending on
budget composition and population health outcomes. Brazil’s constitutional right
to health generates hundreds of thousands of lawsuits per year compelling
municipalities to provide medicines and treatments—often outside the standard
benefit package—within binding budget constraints. Because litigation correlates
with health needs and state capacity, simple comparisons are uninformative. We
exploit the random assignment of judges to health lawsuits: judges differ
persistently in their propensity to grant requests, generating exogenous variation
in court-mandated spending at the municipality level. A distinctive feature of
our data is that line-item municipal budget records from the São Paulo
State Court of Accounts (TCE-SP) directly identify judicial transactions
through explicit judicial-compliance descriptors in the transaction history
field—terms such as “determinação judicial,” “tutela antecipada,” and
“cumprimento de sentença.” These descriptors reveal both the volume of
judicial spending and the budget categories it displaces, providing unusually
direct measurement of the mechanism through which courts reshape public
expenditure.
</p><!-- l. 45 --><p class='indent'>   We make three contributions. First, we document how court mandates reshape
the composition of municipal health budgets. The text-tagged budget data let us
test directly whether judicial spending crowds out primary care in favor of
pharmaceutical spending—the budget categories where court-ordered purchases
                                                                          

                                                                          
concentrate. Combined with evidence on procurement price premia from
emergency judicial purchasing (<a id='x1-1004'></a>Genicolo-Martins &amp; Furquim de Azevedo, <a href='#cite.0@genicolom2024wp'>2024</a>),
this reveals the full channel through which courts alter the marginal product of
the health budget. Second, we provide the first causal estimates linking
court-mandated health spending—measured in budget execution records
rather than estimated from court files—to population health outcomes,
including infant mortality, avoidable hospitalizations, and birth outcomes.
Because the judge instrument operates through municipal budgets, our
estimates capture spillovers to non-litigating patients who share the same
local health system. Third, we characterize the distributional incidence of
judicially allocated resources—a key mechanism through which the mode of
allocation shapes welfare. By linking litigants to employment and social
program registries and testing whether judge-induced spending shocks affect
health outcomes differently across the income distribution, we identify who
bears the costs of crowd-out and who captures the benefits of judicial
mandates.
</p><!-- l. 47 --><p class='indent'>   Health agencies allocate through ex ante screening: formularies, health
technology assessment, and competitive procurement set priorities before
resources are committed. Courts allocate through ex post adjudication: individual
claims trigger spending obligations after the fact. Court mandates function as
rigid ex post earmarks (<a id='x1-1005'></a>Buchanan, <a href='#cite.0@buchanan1963jpe'>1963</a>)—they commit budget resources to
specific patients and treatments, reducing discretionary capacity. Under binding
budget constraints, each real of court-ordered spending displaces other
expenditures. The net health effect depends on what is crowded out and on the
price premium of judicial procurement, which bypasses competitive bidding and
                                                                          

                                                                          
costs 30–44 percent more than equivalent drugs procured through standard
channels (<a id='x1-1006'></a>Genicolo-Martins &amp; Furquim de Azevedo, <a href='#cite.0@genicolom2024wp'>2024</a>). Our design
provides unusually direct evidence on these mechanisms: the budget data
show which categories shrink when judicial spending rises, and the judge
instrument isolates the causal chain from judicial allocation to health
outcomes.
</p><!-- l. 49 --><p class='indent'>   The analysis speaks to a general question in public finance: how the institution
that allocates spending affects its returns. Court-mandated health spending is
growing rapidly in Colombia, Costa Rica, India, and South Africa. More broadly,
the tension arises wherever external authorities impose spending obligations on
local budgets—judicial mandates, intergovernmental earmarks, or regulatory
requirements. Brazil offers three features that make the question tractable:
large-scale litigation that generates substantial fiscal shocks, random assignment
of judges that provides credible identification, and administrative budget records
that reveal the mechanism.
</p><!-- l. 55 --><p class='indent'>   The remainder of the paper is organized as follows. Section <a href='#related-literature'>2<!-- tex4ht:ref: sec:literature  --></a> reviews the
related literature. Section <a href='#institutional-background'>3<!-- tex4ht:ref: sec:background  --></a> describes the institutional background. Section <a href='#data'>4<!-- tex4ht:ref: sec:data  --></a>
presents the data. Section <a href='#empirical-strategy'>5<!-- tex4ht:ref: sec:strategy  --></a> outlines the empirical strategy. Section <a href='#effects-on-health-outcomes'>6<!-- tex4ht:ref: sec:outcomes  --></a> reports the
main results. Section <a href='#who-benefits-distributional-incidence'>7<!-- tex4ht:ref: sec:equity  --></a> examines distributional incidence. Section <a href='#mechanisms-and-budgetary-tradeoffs'>8<!-- tex4ht:ref: sec:mechanisms  --></a> discusses
mechanisms. Section <a href='#robustness-and-extensions'>9<!-- tex4ht:ref: sec:robustness  --></a> presents robustness checks. Section <a href='#discussion-and-policy-implications'>10<!-- tex4ht:ref: sec:discussion  --></a> discusses policy
implications. Section <a href='#conclusion'>11<!-- tex4ht:ref: sec:conclusion  --></a> concludes.
</p><!-- l. 58 --><p class='noindent'>
                                                                          

                                                                          
</p>
   <h3 class='sectionHead' id='related-literature'><span class='titlemark'>2   </span> <a id='x1-20002'></a>Related Literature</h3>
<!-- l. 61 --><p class='noindent'>We contribute to several literatures, organized around five themes: courts and
public resource allocation, the returns to public health spending, the empirical
literature on health judicialization, the distributional consequences of public
spending, and examiner instrumental variable designs.
</p>
<!-- l. 63 --><p class='noindent'><span class='paragraphHead' id='courts-and-public-resource-allocation'><a id='x1-30002'></a><span class='ecbx-1200'>Courts and public resource allocation.</span></span>
   A growing literature studies how courts shape public spending and its
composition. The most developed evidence comes from US school finance
litigation, where court-mandated increases in education spending improve student
achievement and long-run economic outcomes, particularly in low-income
districts (<a id='x1-3001'></a>Hanushek et al., <a href='#cite.0@hanushek2023pfr'>2023</a><a id='x1-3002'></a>; Jackson et al., <a href='#cite.0@jackson2016qje'>2016</a><a id='x1-3003'></a>; Lafortune et al.,
<a href='#cite.0@lafortune2018nber'>2018</a>). Court orders have also been studied in the contexts of desegregation
(<a id='x1-3004'></a>Anstreicher et al., <a href='#cite.0@anstreicher2022nber'>2022</a>) and health care access through Medicaid expansion
(<a id='x1-3005'></a>Borgschulte &amp; Vogler, <a href='#cite.0@borgschulte2020jhe'>2020</a>). A related literature on fiscal federalism studies how
earmarked transfers and mandated spending interact with local budget
constraints. Intergovernmental transfers can have large effects on spending
composition and downstream outcomes (<a id='x1-3006'></a>Litschig &amp; Morrison, <a href='#cite.0@litschig2012aejep'>2012</a>), and
grants tend to “stick where they hit” rather than being offset by local tax
adjustments (<a id='x1-3007'></a>Hines &amp; Thaler, <a href='#cite.0@hinesthaler1995jep'>1995</a>). Court mandates are a distinctive
form of earmark: they are imposed ex post, in response to individual
claims, without the ex ante coordination that characterizes legislative
                                                                          

                                                                          
appropriations. In the Brazilian health context, municipalities operate under
binding minimum spending floors and chronic fiscal constraints (<a id='x1-3008'></a>Funcia &amp;
Ocke-Reis, <a href='#cite.0@funcia2018sd'>2018</a><a id='x1-3009'></a>; Piola et al., <a href='#cite.0@piola2012ipea'>2013</a>), making court-mandated spending a
particularly binding shock that must be financed within rigid budgets,
potentially crowding out discretionary spending on primary care and
prevention (<a id='x1-3010'></a>Maia et al., <a href='#cite.0@maia2024rsp'>2024</a><a id='x1-3011'></a>; Rasella et al., <a href='#cite.0@rasella2018plosmed'>2018</a>). No existing study
provides causal evidence on how this crowd-out mechanism affects health
outcomes.
</p>
<!-- l. 66 --><p class='noindent'><span class='paragraphHead' id='returns-to-public-health-spending'><a id='x1-40002'></a><span class='ecbx-1200'>Returns to public health spending.</span></span>
   A central question motivating our analysis is whether the marginal
health dollar is more productive when allocated administratively—through
primary care and preventive programs—or judicially—through court-ordered
treatments. A large literature on Brazil’s Family Health Strategy (ESF)
demonstrates that primary care expansion substantially reduces infant
mortality (<a id='x1-4001'></a>Aquino et al., <a href='#cite.0@aquino2009ajph'>2009</a><a id='x1-4002'></a>; Macinko et al., <a href='#cite.0@macinko2006jech'>2006</a><a id='x1-4003'></a>; Rocha &amp; Soares, <a href='#cite.0@rochasoares2010he'>2010</a>),
cardiovascular mortality and avoidable hospitalizations (<a id='x1-4004'></a>Hone et al., <a href='#cite.0@hone2017plosmed'>2017</a><a id='x1-4005'></a>;
Rasella et al., <a href='#cite.0@rasella2014bmj'>2014</a>), and racial inequalities in health outcomes (<a id='x1-4006'></a>Hone
et al., <a href='#cite.0@hone2023lancetamericas'>2023</a>; Hone et al., <a href='#cite.0@hone2017plosmed'>2017</a>). Cross-country evidence paints a more
nuanced picture: aggregate health spending shows weak average returns
(<a id='x1-4007'></a>Filmer &amp; Pritchett, <a href='#cite.0@filmer1999wber'>1999</a>), but expansions of coverage and primary care are
consistently associated with improved outcomes (<a id='x1-4008'></a>Bokhari et al., <a href='#cite.0@bokhari2007he'>2007</a><a id='x1-4009'></a>;
Moreno-Serra &amp; Smith, <a href='#cite.0@morenoserra2015jde'>2015</a>). Causal evidence from the United States
                                                                          

                                                                          
confirms that insurance expansions reduce mortality (<a id='x1-4010'></a>Borgschulte &amp; Vogler,
<a href='#cite.0@borgschulte2020jhe'>2020</a><a id='x1-4011'></a>; Finkelstein et al., <a href='#cite.0@finkelstein2019qje'>2019</a>). This literature identifies the returns to
<span class='ecti-1200'>programmatic </span>health spending—planned expansions of coverage, personnel, or
facilities. Our contribution is to estimate the returns to <span class='ecti-1200'>judicially induced</span>
spending, which is non-programmatic, skewed toward high-cost individual
treatments, and may crowd out the very programs shown to be most
effective.
</p>
<!-- l. 69 --><p class='noindent'><span class='paragraphHead' id='health-judicialization'><a id='x1-50002'></a><span class='ecbx-1200'>Health judicialization.</span></span>
   A large descriptive literature documents the growth, composition, and fiscal
costs of health litigation in Brazil (<a id='x1-5001'></a>Biehl et al., <a href='#cite.0@biehl2016hhr'>2016</a><a id='x1-5002'></a>; Diniz et al., <a href='#cite.0@diniz2014csc'>2014</a><a id='x1-5003'></a>;
S. C. P. Oliveira et al., <a href='#cite.0@oliveira2025lancetamericas'>2025</a><a id='x1-5004'></a>; Pepe et al., <a href='#cite.0@pepe2010csp'>2010</a><a id='x1-5005'></a>; Wang &amp; Ferraz, <a href='#cite.0@wangferraz2013sur'>2013</a><a id='x1-5006'></a>; Wang
et al., <a href='#cite.0@wang2014rap'>2014</a>). A first-order concern is supply-side organization: concentrated
networks of lawyers, physicians, and pharmaceutical firms generate a substantial
share of cases, with a small number of attorneys filing the majority of actions for
specific high-cost drugs (<a id='x1-5007'></a>Chieffi &amp; Barata, <a href='#cite.0@chieffibarata2010rsp'>2010</a><a id='x1-5008'></a>; Machado et al., <a href='#cite.0@machado2011rsp'>2011</a><a id='x1-5009'></a>; Soares &amp;
Deprá, <a href='#cite.0@soaresdepra2012physis'>2012</a>). Other strands examine the role of the Defensoría Pública in
shaping access (<a id='x1-5010'></a>Ferraz, <a href='#cite.0@ferraz2009hhr'>2009</a>; Wang &amp; Ferraz, <a href='#cite.0@wangferraz2013sur'>2013</a>) and institutional
responses such as NAT-Jus technical advisory bodies (<a id='x1-5011'></a>Correia et al., <a href='#cite.0@correia2025natjus'>2025</a>).
A parallel comparative literature documents health rights litigation in
Colombia, Costa Rica, and cross-nationally (<a id='x1-5012'></a>Andia &amp; Lamprea, <a href='#cite.0@andialamprea2019bmjgh'>2019</a><a id='x1-5013'></a>;
Arrieta-Gómez, <a href='#cite.0@arrietagomez2018hhr'>2018</a><a id='x1-5014'></a>; Loaiza et al., <a href='#cite.0@loaiza2018hhr'>2018</a><a id='x1-5015'></a>; Yamin, <a href='#cite.0@yamin2010hastings'>2010</a><a id='x1-5016'></a>; Yamin &amp; Gloppen, <a href='#cite.0@yamingloppen2011'>2011</a>).
This body of work provides rich institutional detail but remains almost
                                                                          

                                                                          
entirely descriptive: to our knowledge, no existing study estimates the
<span class='ecti-1200'>causal </span>effect of court-mandated health spending on population health
outcomes.
</p>
<!-- l. 72 --><p class='noindent'><span class='paragraphHead' id='distributional-consequences'><a id='x1-60002'></a><span class='ecbx-1200'>Distributional consequences.</span></span>
   Our analysis of who benefits from judicial spending connects to the literature
on the incidence of public spending in developing countries. Fiscal incidence
studies document that health spending in Brazil is broadly progressive
(<a id='x1-6001'></a>Higgins et al., <a href='#cite.0@higgins2016roiw'>2016</a><a id='x1-6002'></a>; Lustig et al., <a href='#cite.0@lustig2013wd'>2013</a>), but the incidence of <span class='ecti-1200'>judicially
</span><span class='ecti-1200'>allocated </span>spending may differ if access to courts is unequal. The comparative
law-and-development literature highlights the tension between rights-based
litigation as a tool for expanding access and the risk that courts primarily
serve those with greater legal resources (<a id='x1-6003'></a>Ferraz, <a href='#cite.0@ferraz2009hhr'>2009</a><a id='x1-6004'></a>; Gauri &amp; Brinks,
<a href='#cite.0@gauribrinks2008'>2008</a><a id='x1-6005'></a>; Gloppen, <a href='#cite.0@gloppen2006jhr'>2006</a>). <a id='x1-6006'></a>Galanter (<a href='#cite.0@galanter1974lsr'>1974</a>) shows that repeat players with
lower per-case costs systematically outperform one-shotters, and <a id='x1-6007'></a>Shavell
(<a href='#cite.0@shavell1982jls'>1982</a>) demonstrates that private incentives to litigate diverge from social
optimality when litigation costs are unevenly distributed—predicting that
judicial allocation will skew toward better-resourced claimants unless
institutional safeguards lower barriers. Empirical evidence is limited to
descriptive comparisons of litigant profiles with population averages (<a id='x1-6008'></a>Biehl
et al., <a href='#cite.0@biehl2016hhr'>2016</a><a id='x1-6009'></a>; Chieffi &amp; Barata, <a href='#cite.0@chieffi2009csp'>2009</a><a id='x1-6010'></a>; Y. M. C. Oliveira et al., <a href='#cite.0@oliveira2020rsp'>2020</a>). Our
design allows us to go further: by examining how judge-induced spending
shocks affect health outcomes across the income distribution, we provide
                                                                          

                                                                          
causal evidence on whether judicial allocation narrows or widens existing
inequalities.
</p>
<!-- l. 75 --><p class='noindent'><span class='paragraphHead' id='examiner-leniency-designs'><a id='x1-70002'></a><span class='ecbx-1200'>Examiner leniency designs.</span></span>
   Our identification strategy builds on examiner leniency designs, which use
quasi-random assignment of decision-makers as instruments for their decisions
(<a id='x1-7001'></a>Bhuller et al., <a href='#cite.0@bhuller2020'>2020</a><a id='x1-7002'></a>; Chyn et al., <a href='#cite.0@chyn2025jel'>2025</a><a id='x1-7003'></a>; Dobbie et al., <a href='#cite.0@dobbie2018'>2018</a><a id='x1-7004'></a>; Frandsen et al., <a href='#cite.0@frandsen2023aer'>2023</a><a id='x1-7005'></a>;
Goldsmith-Pinkham et al., <a href='#cite.0@goldsmithpinkham2025'>2025</a><a id='x1-7006'></a>; Kling, <a href='#cite.0@kling2006'>2006</a><a id='x1-7007'></a>; Maestas et al., <a href='#cite.0@maestas2013'>2013</a>). Our
application is distinguished by two features: the first stage operates on
municipal budgets rather than individual-level treatment, allowing us to study
population-level consequences including spillovers to non-litigating patients; and
our budget data make the mechanism directly observable—we trace which
expenditure categories expand and which are displaced when judicial spending
rises.
</p><!-- l. 79 --><p class='noindent'>In summary, the closest existing work either documents the descriptive features of
health judicialization without causal identification, or applies examiner leniency
designs in settings—criminal justice, disability insurance, patents—far removed
from health system resource allocation. Our contribution bridges these literatures:
exploiting the judge leniency design within a setting where budget execution data
make the mechanism from judicial allocation to health outcomes directly
observable.
                                                                          

                                                                          
</p><!-- l. 82 --><p class='noindent'>
</p>
   <h3 class='sectionHead' id='institutional-background'><span class='titlemark'>3   </span> <a id='x1-80003'></a>Institutional Background</h3>
<!-- l. 92 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='the-brazilian-public-health-system'><span class='titlemark'>3.1   </span> <a id='x1-90003.1'></a>The Brazilian Public Health System</h4>
<!-- l. 94 --><p class='noindent'>Brazil’s public health system, the Sistema Único de Saúde (SUS), was
established by the 1988 Constitution and implemented through Federal Law
8,080/1990 (<a id='x1-9001'></a>Paim et al., <a href='#cite.0@paim2011lancet'>2011</a>). SUS provides universal, free-of-charge coverage to
all residents regardless of income or employment status. Approximately 75 percent
of the population—roughly 160 million people—relies exclusively on SUS for
health care; the remaining quarter holds supplementary private insurance,
concentrated among higher-income households, though these individuals retain
the right to use SUS services (<a id='x1-9002'></a>Castro et al., <a href='#cite.0@castro2019lancet'>2019</a>).
</p><!-- l. 96 --><p class='indent'>   SUS is financed through general tax revenues from all three levels
of government. Constitutional Amendment 29/2000, later regulated by
Complementary Law 141/2012, established minimum spending floors: states must
allocate at least 12 percent of own-source revenues to health, and municipalities
at least 15 percent. The federal floor was originally linked to nominal
GDP growth but was effectively frozen in real terms by the spending
ceiling amendment (EC 95/2016). As a result, the municipal share of total
public health spending has risen steadily—from 29 percent in 2012 to 34
percent in 2022—while the federal share has declined from 45 to 38 percent.
                                                                          

                                                                          
This fiscal decentralization matters for our analysis. Municipalities bear
increasing financial responsibility for health, yet are also the most exposed to
court-mandated spending. Plaintiffs can sue any level of government, and
enforcement falls on the entity with the most accessible bank accounts
(Section <a href='#allocation-of-costs-across-levels-of-government'>3.4<!-- tex4ht:ref: sec:allocation  --></a>).
</p><!-- l. 98 --><p class='indent'>   Service delivery is organized in three tiers. Primary care is delivered through
the Family Health Strategy (Estratégia Saúde da Família, ESF), a large
community-based program covering over 60 percent of the population (<a id='x1-9003'></a>Macinko
et al., <a href='#cite.0@macinko2006jech'>2006</a>). Secondary and tertiary care are provided through public hospitals,
contracted private providers, and university hospitals organized into regional
referral networks.
</p><!-- l. 100 --><p class='indent'>   Pharmaceutical assistance is organized into three components: the Basic
Component (CBAF), covering primary care medicines and funded primarily by
municipalities; the Strategic Component (CESAF), covering epidemiologically
important diseases and funded federally; and the Specialized Component (CEAF),
covering high-cost treatments for chronic and rare diseases, with cost-sharing
across all three levels of government. The National Essential Medicines List
(RENAME) defines which drugs SUS is obligated to provide. Decisions to
incorporate new technologies into SUS are made by CONITEC (Comissão
Nacional de Incorporação de Tecnologias no SUS), created by Law
12,401/2011, which evaluates proposals based on clinical efficacy, safety, and
cost-effectiveness.
</p><!-- l. 102 --><p class='indent'>   Despite universal coverage in principle, SUS faces persistent gaps between its
legal mandate and actual service delivery (<a id='x1-9004'></a>Castro et al., <a href='#cite.0@castro2019lancet'>2019</a>). Medication
stockouts are widespread: a 2022 national survey found that over 80 percent of
                                                                          

                                                                          
municipalities reported shortages of basic medicines in their public pharmacies
(<a id='x1-9005'></a>Confederação Nacional de Municípios, <a href='#cite.0@cnm2022'>2022</a>). A federal audit found that
none of 25 sampled medications met the statutory 180-day availability
deadline after CONITEC incorporation (<a id='x1-9006'></a>Controladoria-Geral da União,
<a href='#cite.0@cgu2021conitec'>2021</a>).<span class='footnote-mark'><a href='main2.html#fn1x0'><sup class='textsuperscript'>1</sup></a></span><a id='x1-9007f1'></a> 
These gaps between entitlement and access are central to understanding why
patients turn to courts.
</p>
   <h4 class='subsectionHead' id='the-constitutional-right-to-health-and-the-role-of-courts'><span class='titlemark'>3.2   </span> <a id='x1-100003.2'></a>The Constitutional Right to Health and the Role of Courts</h4>
<!-- l. 106 --><p class='noindent' id='introduction'>Article 196 of the 1988 Constitution establishes health as “a right of all and a duty
of the State.” Whether this provision is a programmatic directive—guiding the
state to progressively realize health through policy—or an immediately
enforceable individual entitlement has been the central legal question driving
health judicialization in Brazil (<a id='x1-10001'></a>Ferraz, <a href='#cite.0@ferraz2009hhr'>2009</a><a id='x1-10002'></a>; Wang, <a href='#cite.0@wang2015hepl'>2015</a>).
</p><!-- l. 108 --><p class='indent'>   Beginning in the late 1990s, the Supreme Federal Tribunal (STF) decisively
adopted the latter interpretation. In a landmark 1997 decision, the STF
ordered a state to fund treatment abroad for a child with a rare disease,
                                                                          

                                                                          
holding that the individual right to health takes precedence over fiscal
constraints.<span class='footnote-mark'><a href='main3.html#fn2x0'><sup class='textsuperscript'>2</sup></a></span><a id='x1-10003f2'></a> 
This reasoning—treating the constitutional provision as an individual, justiciable
entitlement to specific treatments—was rapidly adopted by lower courts across the
country.
</p><!-- l. 110 --><p class='indent'>   The result was a rapid growth in individualized health litigation. Courts
routinely granted preliminary injunctions (<span class='ecti-1200'>liminares</span>) compelling immediate
delivery of medicines, procedures, or hospital care, with plaintiff success
rates consistently exceeding 90 percent (<a id='x1-10004'></a>Biehl et al., <a href='#cite.0@biehl2012hhr'>2012</a>). <a id='x1-10005'></a>Ferraz (<a href='#cite.0@ferraz2009hhr'>2009</a>)
characterizes the resulting “Brazilian model” of health litigation as one marked by
individualized claims, demand for curative treatments, and near-universal plaintiff
success. By the late 2000s, the phenomenon had reached a scale that prompted
institutional responses from the judiciary itself, the legislature, and the executive
branch.
</p>
   <h4 class='subsectionHead' id='types-of-health-lawsuits'><span class='titlemark'>3.3   </span> <a id='x1-110003.3'></a>Types of Health Lawsuits</h4>
<!-- l. 114 --><p class='noindent'>Medicines dominate health litigation, comprising approximately 80 percent of
cases (<a id='x1-11001'></a>Tribunal de Contas da União, <a href='#cite.0@tcu2017'>2017</a>). Over half of medication lawsuits in
some jurisdictions request drugs already on SUS formularies, suggesting that
much litigation addresses administrative delivery failures rather than genuine
                                                                          

                                                                          
coverage gaps (<a id='x1-11002'></a>Biehl et al., <a href='#cite.0@biehl2009lancet'>2009</a><a id='x1-11003'></a>; Chieffi &amp; Barata, <a href='#cite.0@chieffi2009csp'>2009</a>). The remainder request
medicines not incorporated into the national formulary, including some without
ANVISA registration. High-cost treatments for cancer, rare diseases, and chronic
conditions account for a disproportionate share of judicial spending—more
than half of federal judicial health expenditures between 2010 and 2015
were concentrated in just three medicines not on the essential list (<a id='x1-11004'></a>Vieira,
<a href='#cite.0@vieira2020hhr'>2020</a>).<span class='footnote-mark'><a href='main4.html#fn3x0'><sup class='textsuperscript'>3</sup></a></span><a id='x1-11005f3'></a> 
This on-formulary versus off-formulary distinction matters for interpretation:
crowd-out of on-formulary drugs signals administrative failure that courts correct,
while off-formulary orders impose genuinely new spending obligations.
</p><!-- l. 116 --><p class='indent'>   Beyond medicines, lawsuits seek surgical procedures, hospital beds, and
medical devices. Cases are overwhelmingly individual; collective actions account
for only 3 percent of first-instance health cases at TJSP. In TJSP, private
attorneys represent the vast majority of plaintiffs, with the Defensoria Pública
(Public Defender’s Office) handling only about 7 percent of first-instance health
decisions—consistent with unequal access to litigation that we examine in
Section <a href='#who-benefits-distributional-incidence'>7<!-- tex4ht:ref: sec:equity  --></a>.
</p><!-- l. 118 --><p class='indent'>   The scale of health litigation has grown rapidly. Federal spending on judicial
compliance for medicines rose thirteen-fold in seven years, from R$70
million in 2008 to over R$1 billion by 2015 (<a id='x1-11007'></a>Tribunal de Contas da União,
<a href='#cite.0@tcu2017'>2017</a>), reaching R$1.9 billion by 2024 (<a id='x1-11008'></a>Instituto de Pesquisa Econômica
                                                                          

                                                                          
Aplicada, <a href='#cite.0@ipea2025'>2025</a>). At the state level, court-mandated medications represented
approximately one-third of total pharmaceutical spending in 2023. Over
160,000 new first-instance public health cases were filed nationally in 2024
alone.
</p>
   <h4 class='subsectionHead' id='allocation-of-costs-across-levels-of-government'><span class='titlemark'>3.4   </span> <a id='x1-120003.4'></a>Allocation of Costs Across Levels of Government</h4>
<!-- l. 123 --><p class='noindent'>Under the doctrine of solidary liability (<span class='ecti-1200'>responsabilidade solidária</span>), all three
levels of government—federal, state, and municipal—can be sued for health
provision. This follows from the constitutional assignment of “common
competence” over health (Art. 23, II). In practice, plaintiffs may sue any entity or
combination of entities, without a required order of preference. The result is a
vertical fiscal externality: courts impose spending obligations on municipal
budgets that violate the principle of matching expenditure responsibilities to
revenue capacity (<a id='x1-12001'></a>Oates, <a href='#cite.0@oates1999jel'>1999</a>).
</p><!-- l. 125 --><p class='indent'>   In 2019, the STF attempted to rationalize this arrangement (Tema 793, RE
855.178). The ruling maintained solidary liability but directed judges to assign
compliance to the responsible entity under SUS’s own allocation rules and
to require inter-governmental reimbursement. In practice, lower courts
continue to apply solidary liability without consistently directing compliance
to the appropriate entity. Throughout most of our sample period, no
systematic federal reimbursement mechanism existed for municipalities
condemned in state courts. Only in 2024 did the STF establish that the federal
government must reimburse 65 percent of costs when states or municipalities are
                                                                          

                                                                          
ordered to provide non-incorporated drugs costing between 7 and 210
minimum salaries (Temas 1,234 and 6). Our data capture the period of
maximum municipal fiscal exposure, when court orders fell entirely on local
budgets.
</p><!-- l. 127 --><p class='indent'>   The result is that municipalities frequently bear costs that should fall on
states or the federal government. A study of the municipality of São
Paulo found that 55 percent of court-mandated pharmaceutical spending
corresponded to medicines that were the responsibility of the state or
federal government (<a id='x1-12002'></a>Wang et al., <a href='#cite.0@wang2014rap'>2014</a>). Municipalities have the least fiscal
capacity but face the most enforcement pressure: when a public entity fails
to comply, judges can order the immediate seizure (<span class='ecti-1200'>bloqueio</span>) of funds
from government bank accounts. A single court order can disrupt planned
expenditures in a small municipality’s health account. This vertical mismatch
generates a testable prediction: the fiscal and health consequences of court
mandates should be larger in municipalities with lower own-source fiscal
capacity, and in settings where mandated items fall outside municipal
responsibility.
</p><!-- l. 129 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='key-jurisprudence-shaping-judicial-behavior'><span class='titlemark'>3.5   </span> <a id='x1-130003.5'></a>Key Jurisprudence Shaping Judicial Behavior</h4>
<!-- l. 131 --><p class='noindent'>Between 2009 and 2019, a series of rulings by the STF and STJ introduced
constraints on judicial health orders—technical advisory requirements, evidentiary
standards for non-incorporated medicines, and a bar on drugs without regulatory
                                                                          

                                                                          
registration (details in Appendix <a href='#detailed-jurisprudence'>A<!-- tex4ht:ref: sec:jurisprudence_appendix  --></a>).
</p><!-- l. 133 --><p class='indent'>   Despite these formal constraints, there is little evidence that they substantially
changed judicial behavior during our sample period. At TJSP—our main
court—technical advisory notes (NAT-Jus) were cited in fewer than 0.01
percent of first-instance health decisions: 9 of 107,497 cases (<a id='x1-13001'></a>CNJ/INSPER,
<a href='#cite.0@cnjinsper2019'>2019</a>).<span class='footnote-mark'><a href='main5.html#fn4x0'><sup class='textsuperscript'>4</sup></a></span><a id='x1-13002f4'></a> 
The volume of health litigation continued to accelerate through the 2020s, and
grant rates for medication requests against municipalities at TJSP remain
approximately 93 percent. The institutional framework has shifted toward more
structured criteria, but these have not eliminated the substantial judge-level
variation in decision-making that we exploit. In 2024, the STF introduced binding
administrative exhaustion requirements and a federal reimbursement mechanism;
our analysis focuses on the pre-reform period when judicial discretion was largely
                                                                          

                                                                          
unconstrained.<span class='footnote-mark'><a href='main6.html#fn5x0'><sup class='textsuperscript'>5</sup></a></span><a id='x1-13003f5'></a> 
</p>
   <h4 class='subsectionHead' id='why-courts-affect-local-health-budgets'><span class='titlemark'>3.6   </span> <a id='x1-140003.6'></a>Why Courts Affect Local Health Budgets</h4>
<!-- l. 137 --><p class='noindent'>Several features of health litigation make court orders consequential
for municipal budgets. First, compliance is mandatory and swiftly
enforced. The typical preliminary injunction at TJSP is granted within
10 days of filing and requires compliance within 24 hours to 15 days.
Non-compliance triggers direct seizure of funds from municipal bank
accounts, daily fines, and potential personal criminal liability for public
officials.<span class='footnote-mark'><a href='main7.html#fn6x0'><sup class='textsuperscript'>6</sup></a></span><a id='x1-14001f6'></a> 
Second, treatments are considered irreversible once consumed, so the
fiscal impact is locked in at the preliminary stage. Even if the decision
is later reversed on appeal, the municipality almost never recovers its
                                                                          

                                                                          
expenditure. Third, many orders mandate continuous provision of chronic disease
medications, creating recurring budget commitments that accumulate over
time. The cumulative stock of active orders—not just the flow of new
cases—determines the fiscal burden, motivating the dynamic analysis in
Section <a href='#effects-on-health-outcomes'>6<!-- tex4ht:ref: sec:outcomes  --></a>.
</p><!-- l. 139 --><p class='indent'>   The fiscal burden is amplified by procurement inefficiency. Court orders require
urgent compliance, so municipalities must purchase drugs through emergency
procurement (<span class='ecti-1200'>dispensa de licitação</span>), bypassing competitive bidding. <a id='x1-14002'></a>Genicolo-Martins
and Furquim de Azevedo (<a href='#cite.0@genicolom2024wp'>2024</a>) estimate that court-mandated drug purchases
cost 30–44 percent more than equivalent drugs procured through standard SUS
channels.<span class='footnote-mark'><a href='main8.html#fn7x0'><sup class='textsuperscript'>7</sup></a></span><a id='x1-14003f7'></a> 
The premium reflects retail-quantity purchases, brand-name mandates, and
strategic pricing by pharmaceutical firms that delay SUS incorporation to profit
from the higher-priced judicial channel. Each real of judicial spending
thus displaces more than one real of planned health expenditure. Because
court orders create non-discretionary spending within a constitutionally
mandated health budget floor, they crowd out planned allocations to other
programs—primarily primary care, prevention, and population-level interventions
(<a id='x1-14005'></a>Ferraz, <a href='#cite.0@ferraz2009hhr'>2009</a>).
</p><!-- l. 141 --><p class='indent'>   The next sections describe the data and empirical strategy we use to estimate
these returns.
                                                                          

                                                                          
</p>
   <h3 class='sectionHead' id='data'><span class='titlemark'>4   </span> <a id='x1-150004'></a>Data</h3>
<!-- l. 147 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='health-lawsuits'><span class='titlemark'>4.1   </span> <a id='x1-160004.1'></a>Health Lawsuits</h4>
<!-- l. 149 --><p class='noindent'>Our litigation data cover São Paulo, the state with the highest volume of health
cases and the setting where budget and case records can be linked at the
transaction level. We draw on two courts: the Tribunal de Justiça de São Paulo
(TJSP) for cases against municipalities and the state, and the Tribunal Regional
Federal da 3<span class='tcrm-1200'>ª </span>Região (TRF3) for cases against the federal government. We
identify health cases in the DataJud national repository (<a id='x1-16001'></a>Conselho Nacional de
Justiça, <a href='#cite.0@datajud'>2020</a>), which provides structured metadata (case number, court, filing
date, subject codes, parties, judge) for all cases from 2020 onward. We
supplement DataJud with the official electronic gazette (available from 2007
for TJSP) and full-text decisions from the Consulta de Julgados portal
(<a id='x1-16002'></a>Tribunal de Justiça do Estado de São Paulo, <a href='#cite.0@tjsp_esaj'>2024</a>), available from 2014 for
TJSP.<span class='footnote-mark'><a href='main9.html#fn8x0'><sup class='textsuperscript'>8</sup></a></span><a id='x1-16003f8'></a> 
From full-text decisions we extract the treatment requested, diagnosis,
grant/deny outcome, and deciding judge—the building blocks for the
                                                                          

                                                                          
judge stringency instrument and the municipality-level judicial spending
measure.
</p><!-- l. 151 --><p class='indent'>   Cases at both TJSP and TRF3 are assigned to judges through an automated
sequential distribution system within each court; we describe the assignment
mechanism and address exceptions (related-case routing [<span class='ecti-1200'>prevenção</span>],
entity-dimension forum shopping) in Section <a href='#empirical-strategy'>5<!-- tex4ht:ref: sec:strategy  --></a>.
</p>
   <h4 class='subsectionHead' id='health-spending-and-budgets'><span class='titlemark'>4.2   </span> <a id='x1-170004.2'></a>Health Spending and Budgets</h4>
<!-- l. 157 --><p class='noindent'>Our primary source for municipal health spending is the line-item expenditure
data published by the Tribunal de Contas do Estado de São Paulo (TCE-SP)
through its transparency portal (<a id='x1-17001'></a>Tribunal de Contas do Estado de São Paulo,
<a href='#cite.0@tcesp_audesp'>2024</a>). These data originate from the Audesp (Auditoria Eletrônica de
Órgãos Públicos) system, which requires all 644 municipalities under
TCE-SP jurisdiction to report every budget execution event—commitment
(<span class='ecti-1200'>empenho</span>), verification (<span class='ecti-1200'>liquidação</span>), and payment (<span class='ecti-1200'>pagamento</span>)—in a
standardized electronic format. The resulting dataset provides transaction-level
records of municipal health expenditures from 2008 to 2024, classified
by the functional-programmatic budget structure (Portaria 42/1999):
function (<span class='ecti-1200'>função</span>), subfunction (<span class='ecti-1200'>subfunção</span>), program (<span class='ecti-1200'>programa</span>),
and expenditure type (<span class='ecti-1200'>natureza da despesa</span>). Revenue source (<span class='ecti-1200'>fonte de
</span><span class='ecti-1200'>recurso</span>) distinguishes federal SUS transfers from own-source municipal
revenues.
</p><!-- l. 159 --><p class='indent'>   A key feature of the TCE-SP data is the transaction history field
                                                                          

                                                                          
(<span class='ecti-1200'>histórico</span>)—a free-text description accompanying each expenditure entry that
records the legal and administrative basis for the transaction. We identify
court-mandated spending by searching this field for explicit judicial-compliance
descriptors such as “determinação judicial,” “tutela antecipada,” and
“cumprimento de sentença” (the full list of descriptors and validation procedures
are in Appendix <a href='#data-construction-details'>B<!-- tex4ht:ref: sec:data_appendix  --></a>). This identification captures actual expenditures incurred to
comply with court orders, providing a direct measure of the fiscal burden of health
litigation at the municipality-month level—without requiring us to estimate costs
from court records.
</p><!-- l. 161 --><p class='indent'>   To examine how court orders affect the composition of health
spending, we exploit the subfunction classification within the Health
function. The six health subfunctions—Primary Care, Hospital and
Outpatient Care, Pharmaceutical and Therapeutic Support, Health
Surveillance, Epidemiological Surveillance, and Nutrition—have remained
stable since 1999, ensuring consistent definitions across our sample
period.<span class='footnote-mark'><a href='main10.html#fn9x0'><sup class='textsuperscript'>9</sup></a></span><a id='x1-17002f9'></a> 
This allows us to test directly whether judicial spending crowds out Primary Care
in favor of Pharmaceutical and Therapeutic Support, the category where
                                                                          

                                                                          
court-ordered purchases concentrate. We supplement the TCE-SP data with
SIOPS (Sistema de Informações sobre Orçamentos Públicos em Saúde;<a id='x1-17003'></a>
Ministério da Saúde, <a href='#cite.0@siops'>2024d</a>) for cross-validation and for comparison with
municipalities outside São Paulo.
</p><!-- l. 163 --><p class='indent'>   TCE-SP covers all 644 municipalities in the state of São Paulo except the
capital, which falls under the separate jurisdiction of the Tribunal de Contas
do Município de São Paulo (TCM-SP). Health litigation at TJSP is
concentrated in the interior: approximately 77 percent of health cases are filed
in the 321 judicial districts (<span class='ecti-1200'>comarcas</span>) outside the capital, handled by
over 3,000 judges. The capital accounts for the remaining 23 percent.
Our spending data therefore cover the jurisdictions where most health
litigation occurs. We discuss the implications of excluding the capital in
Section <a href='#robustness-and-extensions'>9<!-- tex4ht:ref: sec:robustness  --></a>.
</p>
   <h4 class='subsectionHead' id='health-outcomes'><span class='titlemark'>4.3   </span> <a id='x1-180004.3'></a>Health Outcomes</h4>
<!-- l. 169 --><p class='noindent'>We measure health outcomes using individual-level microdata from three
DATASUS registries: hospital admissions (SIH/SUS) (<a id='x1-18001'></a>Ministério da Saúde,
<a href='#cite.0@datasus_sih'>2024a</a>), mortality (SIM) (<a id='x1-18002'></a>Ministério da Saúde, <a href='#cite.0@datasus_sim'>2024b</a>), and live births
(SINASC) (<a id='x1-18003'></a>Ministério da Saúde, <a href='#cite.0@datasus_sinasc'>2024c</a>). The SIH records every hospitalization
funded by SUS, including patient municipality, admission and discharge dates,
primary and secondary diagnoses (ICD-10), procedure codes, age, sex, and cost.
SIM covers the universe of deaths with cause (ICD-10), municipality, date, and
demographic characteristics. Both registries are available from approximately 2000
                                                                          

                                                                          
onward, covering our full sample period. SINASC records all live births
with birth weight, gestational age, prenatal visit count, and maternal
characteristics.
</p><!-- l. 171 --><p class='indent'>   Individual-level microdata enable three capabilities beyond municipality-year
aggregates from DATASUS tabulations. First, we construct cause-specific and
age-stratified outcomes: avoidable hospitalizations (ICSAP criteria; <a id='x1-18004'></a>Alfradique
et al., <a href='#cite.0@alfradique2009csp'>2009</a>) decomposed by condition family (cardiovascular, respiratory,
infectious), amenable mortality by age group, and birth outcomes. Second, we
aggregate outcomes at the municipality-month or municipality-quarter level rather
than municipality-year, exploiting the higher-frequency variation in judicial
spending available from TCE-SP budget records. Third, by linking litigant names
to SIH and SIM records (Section <a href='#sample-construction-and-limitations'>4.5<!-- tex4ht:ref: sec:sample  --></a>), we can partition outcomes into litigant and
non-litigant components, enabling separate estimation of direct benefits and
population spillovers.
</p><!-- l. 173 --><p class='indent'>   For intermediate (mechanism) outcomes we draw on ESF coverage (number of
active Family Health Strategy teams per municipality, from the Ministry of
Health’s e-Gestor platform) and vaccination coverage (from the National
Immunization Program, PNI). For placebo tests, we use educational attainment
from the School Census (INEP), formal employment from RAIS, and nighttime
light intensity from VIIRS satellite data.
</p><!-- l. 177 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='socioeconomic-characteristics'><span class='titlemark'>4.4   </span> <a id='x1-190004.4'></a>Socioeconomic Characteristics</h4>
                                                                          

                                                                          
<!-- l. 179 --><p class='noindent'>We draw on two individual-level administrative registries. RAIS (Relação Anual
de Informações Sociais) is the annual census of formal-sector employment,
covering the universe of formal employment relationships with earnings,
occupation, employer, and employment duration (<a id='x1-19001'></a>Ministério do Trabalho e
Emprego, <a href='#cite.0@rais'>2024</a>). We use RAIS both to profile litigants (earnings level, sector,
employment trajectory) and as an individual-level outcome source: for
linked litigants, we construct pre- and post-filing earnings and employment
indicators to estimate the direct labor-market effects of winning a health
lawsuit. CadÚnico (Cadastro Único) is the registry for social programs
targeting low-income families (<a id='x1-19002'></a>Ministério do Desenvolvimento e Assistência
Social, <a href='#cite.0@cadunico'>2024</a>), which identifies individuals at the bottom of the income
distribution and captures participation in Bolsa Família and other transfer
programs.
</p><!-- l. 181 --><p class='indent'>   We link individuals across litigation records, SIH, SIM, RAIS, and CadÚnico
using a complete Brazilian name registry that covers all formally registered
names. Approximately 50 percent of full names in the registry are nationally
unique, enabling deterministic matching without probabilistic record linkage
for those individuals. Our baseline linkage restricts to verified unique
names—individuals whose full name appears exactly once in both the litigation
records and the target registry within the relevant state and year. This
conservative approach sacrifices coverage for precision; we assess robustness to
alternative linkage criteria in Section <a href='#robustness-and-extensions'>9<!-- tex4ht:ref: sec:robustness  --></a> and Appendix <a href='#namelinkage-procedure'>B.4<!-- tex4ht:ref: sec:app_linkage  --></a>. At the municipality
level, we complement individual-level linkage with aggregate socioeconomic
controls from the Brazilian Census and PNAD.
                                                                          

                                                                          
</p><!-- l. 183 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='sample-construction-and-limitations'><span class='titlemark'>4.5   </span> <a id='x1-200004.5'></a>Sample Construction and Limitations</h4>
<!-- l. 186 --><p class='noindent'>Our main analysis sample covers health lawsuits filed at TJSP from 2014 onward,
the period for which full-text decisions are available through Consulta de
Julgados. We extend the sample back to 2007 using the Diário de Justiça for
analyses that require only case-level indicators (filing, grant/deny, judge
assignment) rather than detailed treatment information. TRF3 cases from 2011
onward supplement the TJSP data, though for the federal court we rely solely on
the gazette and therefore have less granular information on treatment
requests.
</p><!-- l. 188 --><p class='indent'>   The name-linkage procedure is relevant only for the litigant direct-effects
analysis (Section <a href='#litigantlevel-estimating-equations'>5.4<!-- tex4ht:ref: sec:litigant_equations  --></a>); population-level and non-litigant spillover analyses do not
require individual linkage. For litigant analyses, we match plaintiff names from
court records to SIH, SIM, and RAIS using the complete name registry. We report
a selection table comparing linked and unlinked litigants on observable
case characteristics (court, filing year, grant rate, case type, attorney
type, municipality of origin). Because name uniqueness may correlate
with socioeconomic status and ethnicity, we construct inverse probability
weights (IPW) based on a model of linkage probability conditional on
observables, and report IPW-reweighted estimates alongside unweighted
results. We also stratify results by propensity of name uniqueness to assess
sensitivity.
</p><!-- l. 190 --><p class='indent'>   To summarize coverage: litigation records span 2007–present (gazette),
2014–present (full-text decisions), and 2020–present (DataJud structured
                                                                          

                                                                          
metadata); TCE-SP budget data cover 2008–2024; SIH and SIM microdata cover
approximately 2000–present; RAIS is available annually; SINASC covers
all years. Our main analysis uses the intersection of full-text decisions
(2014+) and budget data (2008+), yielding a primary estimation sample of
2014–2024.
</p><!-- l. 192 --><p class='indent'>   Three additional scope issues deserve note. Our judicial spending measure
captures expenditures that municipalities tag as court-mandated in the
transaction history field; we cross-validate against court-records-based spending
estimates to assess coverage. Health outcome data from DATASUS cover
SUS-funded services only, which is the relevant population for our analysis since
these patients are most affected by municipal budget reallocations. For
non-litigant outcome construction (Section <a href='#populationlevel-estimating-equations'>5.3<!-- tex4ht:ref: sec:population_equations  --></a>), we exclude linked litigants
from SIH and SIM records before aggregating to the municipality-period
level; the excluded share is small relative to total hospitalizations and
deaths, so the non-litigant outcomes closely approximate population-level
measures.
</p><!-- l. 200 --><p class='noindent'>
</p>
   <h3 class='sectionHead' id='empirical-strategy'><span class='titlemark'>5   </span> <a id='x1-210005'></a>Empirical Strategy</h3>
<!-- l. 203 --><p class='noindent'>
</p>
                                                                          

                                                                          
   <h4 class='subsectionHead' id='conceptual-framework'><span class='titlemark'>5.1   </span> <a id='x1-220005.1'></a>Conceptual Framework</h4>
<!-- l. 205 --><p class='noindent'>Consider a municipality with a fixed health budget <span class='cmmi-12'>B </span>that an administrator
allocates across programs to maximize population health. Courts impose
mandatory spending <span class='cmmi-12'>J </span>on specific treatments for individual litigants, reducing the
discretionary budget to <span class='cmmi-12'>B </span><span class='cmsy-10x-x-120'>−</span><span class='cmmi-12'>J</span>. Because judicial procurement bypasses competitive
bidding, each real of court-ordered spending costs a factor <span class='cmmi-12'>p &gt; </span><span class='cmr-12'>1 </span>more
than equivalent administrative purchases, so the effective displacement is
<span class='cmmi-12'>pJ</span>.<span class='footnote-mark'><a href='main11.html#fn10x0'><sup class='textsuperscript'>10</sup></a></span><a id='x1-22001f10'></a> 
This setup generates three testable predictions, whose signs depend on which of
two polar views of courts is operative at the margin.
</p><!-- l. 207 --><p class='indent'>   Under the <span class='ecti-1200'>corrective </span>view, courts remedy genuine failures of administrative
delivery—SUS promises treatments it does not provide, and judicial orders
compel compliance with existing entitlements. Under the <span class='ecti-1200'>distortionary </span>view,
courts override administrative priority-setting, channeling resources toward
individually litigated treatments with lower marginal returns than the
programmatic spending they displace. The two views generate identical
predictions for budget composition (Prediction 1: both imply displacement of
discretionary spending) but diverge sharply on the sign of health effects
(Prediction 2) and on where effects are largest. The corrective view predicts
health improvements concentrated where administrative capacity is weakest and
                                                                          

                                                                          
for treatments already on the formulary; the distortionary view predicts
negative net effects, concentrated where litigation is supply-driven and
mandates fall outside existing benefit packages. Our heterogeneity analyses
(Sections <a href='#who-benefits-distributional-incidence'>7<!-- tex4ht:ref: sec:equity  --></a> and <a href='#supplyside-drivers-lawyer-concentration-and-pharmaceutical-networks'>8.4<!-- tex4ht:ref: sec:supplyside  --></a>) are designed to distinguish these views, focusing on
administrative capacity, formulary status, fiscal mismatch, and supply-driven
litigation.
</p><!-- l. 209 --><p class='indent'>   <span class='ecti-1200'>Prediction 1: Budget composition. </span>Court mandates shift spending from
programmatic categories—primary care, prevention, epidemiological
surveillance—toward pharmaceutical and therapeutic spending, the categories
where court-ordered purchases concentrate. The displacement is amplified by the
procurement premium: a court order for one real of treatment reduces other
spending by more than one real. Our budget data, with text-tagged judicial
transactions classified by subfunction, allow us to test this prediction
directly.
</p><!-- l. 211 --><p class='indent'>   <span class='ecti-1200'>Prediction 2: Population health. </span>The net effect on population health
depends on relative marginal returns. If displaced programmatic
spending (primary care, vaccination, prenatal services) has higher
marginal returns than court-ordered treatments (typically high-cost,
individualized, curative), court mandates reduce population health on
                                                                          

                                                                          
net.<span class='footnote-mark'><a href='main12.html#fn11x0'><sup class='textsuperscript'>11</sup></a></span><a id='x1-22004f11'></a> 
The sign is an empirical question that our judge IV design can answer. We
benchmark the estimated return to court-mandated spending against the return
to administrative health expenditure, estimated separately using variation in
federal transfers (Section <a href='#effects-on-health-outcomes'>6<!-- tex4ht:ref: sec:outcomes  --></a>).
</p><!-- l. 213 --><p class='indent'>   <span class='ecti-1200'>Prediction 3: Distributional incidence. </span>If access to litigation is positively correlated
with socioeconomic status, court mandates transfer health budget resources from the
general population—who bear the cost of crowd-out—to a selected subpopulation of
litigants.<span class='footnote-mark'><a href='main13.html#fn12x0'><sup class='textsuperscript'>12</sup></a></span><a id='x1-22007f12'></a> 
The net distributional effect depends on two margins: who litigates (direct
beneficiaries of court orders) and whose care is displaced (those who depend on
the crowded-out programs). We test this by linking litigants to income registries
and examining whether judge-induced spending shocks affect health outcomes
differently across the income distribution.
                                                                          

                                                                          
</p><!-- l. 215 --><p class='indent'>   A further consideration is that the marginal cases induced by lenient judges
may be disproportionately supply-driven—generated by concentrated
lawyer-physician-pharmaceutical networks rather than by patient need. We
probe this in Section <a href='#supplyside-drivers-lawyer-concentration-and-pharmaceutical-networks'>8.4<!-- tex4ht:ref: sec:supplyside  --></a> by splitting cases by the concentration of legal
representation.
</p>
   <h4 class='subsectionHead' id='identification'><span class='titlemark'>5.2   </span> <a id='x1-230005.2'></a>Identification</h4>
<!-- l. 219 --><p class='noindent'>Judicial health spending is endogenous. Municipalities with sicker populations,
weaker public health systems, or more active legal aid organizations are likely
to experience both more health litigation and worse health outcomes.
Correlations between judicial spending and health outcomes therefore
confound the effect of courts with the underlying conditions that drive
litigation.
</p><!-- l. 221 --><p class='indent'>   We address this challenge by exploiting quasi-random variation in judge
assignments. In the Brazilian first-instance judiciary, cases filed at a given trial
court (<span class='ecti-1200'>vara</span>) are assigned to judges through an automated, sequential distribution
system designed to ensure balanced workloads and prevent judge selection. In
judicial districts with multiple public-law trial courts (<span class='ecti-1200'>varas da fazenda pública</span>),
CNJ Resolution 238/2016 mandates that one court specialize in public health
cases. Health cases are therefore randomly assigned among judges within the
designated health court, conditional on the district and filing period. Litigants
and their attorneys cannot select or influence which judge is assigned to their
case.
                                                                          

                                                                          
</p><!-- l. 223 --><p class='indent'>   Judges differ persistently in their propensity to grant health requests, even
when facing similar cases within the same court. This variation in judicial
behavior—judge “stringency”—generates exogenous shocks to the volume and
cost of court-mandated health spending. Because technical screening was
rarely binding during our sample period (Section <a href='#institutional-background'>3<!-- tex4ht:ref: sec:background  --></a>), this variation reflects
meaningful judicial discretion rather than differential adherence to clinical
guidelines.
</p><!-- l. 225 --><p class='indent'>   We measure judge stringency using a leave-one-out (jackknife) estimator
(<a id='x1-23001'></a>Bhuller et al., <a href='#cite.0@bhuller2020'>2020</a><a id='x1-23002'></a>; Kling, <a href='#cite.0@kling2006'>2006</a><a id='x1-23003'></a>; Maestas et al., <a href='#cite.0@maestas2013'>2013</a>). For each case <span class='cmmi-12'>i </span>assigned
to judge <span class='cmmi-12'>j </span>in court <span class='cmmi-12'>c </span>at time <span class='cmmi-12'>t</span>, we define the instrument as:
</p>
   <table class='equation'><tr><td>
   <div class='math-display'>
<img alt='        ---1----  ∑
Zijct = n   − 1         Dk,
         jct     k⁄=i:j(k)=j
' class='math-display' src='main0x.png' /><a id='x1-23004r1'></a></div>
   </td><td class='equation-label'>(1)</td></tr></table>
<!-- l. 230 --><p class='nopar'>
where <span class='cmmi-12'>D</span><sub><span class='cmmi-8'>k</span></sub> is an indicator (or a measure of the cost) of granting the request in
case <span class='cmmi-12'>k</span>, and the sum is over all other cases assigned to judge <span class='cmmi-12'>j </span>in the
                                                                          

                                                                          
same court-year cell. The leave-one-out construction ensures that the
instrument for case <span class='cmmi-12'>i </span>is not mechanically related to the outcome of case <span class='cmmi-12'>i</span>
itself.
</p><!-- l. 234 --><p class='indent'>   Because our outcomes of interest—population health measures—are observed
at the municipality level, we aggregate the case-level instrument to that unit of
analysis. Specifically, we average the instrument across all cases originating in
municipality <span class='cmmi-12'>m </span>at time <span class='cmmi-12'>t</span>:
</p>
   <table class='equation'><tr><td>
   <div class='math-display'>
<img alt='¯      -1--∑
Zmt =  n       Zijct,
        mt i∈m,t
' class='math-display' src='main1x.png' /><a id='x1-23005r2'></a></div>
   </td><td class='equation-label'>(2)</td></tr></table>
<!-- l. 239 --><p class='nopar'>
where <span class='cmmi-12'>n</span><sub><span class='cmmi-8'>mt</span></sub> is the number of health cases filed from municipality <span class='cmmi-12'>m </span>in period <span class='cmmi-12'>t</span>.
Municipalities whose cases happen to be assigned to more lenient judges receive a positive
shock to court-mandated spending; those assigned to stricter judges receive a negative
                                                                          

                                                                          
shock.<span class='footnote-mark'><a href='main14.html#fn13x0'><sup class='textsuperscript'>13</sup></a></span><a id='x1-23006f13'></a> 
</p><!-- l. 243 --><p class='indent'>   The same source of exogenous variation—random judge assignment—maps to
two tiers of analysis. At the municipality level, judge leniency aggregated across
cases filed from a given municipality generates exogenous shocks to the volume of
court-mandated spending, enabling estimation of population-level effects on
budgets, health outcomes, and non-litigant spillovers (Section <a href='#populationlevel-estimating-equations'>5.3<!-- tex4ht:ref: sec:population_equations  --></a>). At the case
level, the leniency of the judge assigned to a specific plaintiff generates exogenous
variation in whether the request is granted, enabling estimation of the direct effect
on litigant health and labor-market outcomes (Section <a href='#litigantlevel-estimating-equations'>5.4<!-- tex4ht:ref: sec:litigant_equations  --></a>). The two tiers share
identification assumptions but differ in the unit of analysis, the endogenous
variable, and the estimand.
</p><!-- l. 245 --><p class='indent'>   Three setting-specific threats to identification deserve
attention.<span class='footnote-mark'><a href='main15.html#fn14x0'><sup class='textsuperscript'>14</sup></a></span><a id='x1-23008f14'></a> 
                                                                          

                                                                          
First, related-case routing rules (<span class='ecti-1200'>prevenção</span>) direct connected cases to
the original judge, creating non-random clustering; we address this by
excluding linked cases from the leave-one-out calculation. Second, litigants
choose which level of government to sue, but this entity-dimension forum
shopping does not affect judge assignment <span class='ecti-1200'>within </span>a given court. Third,
lenient judges may affect health through non-spending channels: granting
interim relief faster, imposing fund seizures (<span class='ecti-1200'>bloqueio</span>), setting daily fines
(<span class='ecti-1200'>astreintes</span>), or creating personal liability threats for officials—all of which could
independently disrupt municipal health administration. Our estimand is therefore
best interpreted as the effect of “judicial intensity” broadly, not spending
alone; we address this by examining whether the instrument predicts
non-spending enforcement actions in Section <a href='#robustness-and-extensions'>9<!-- tex4ht:ref: sec:robustness  --></a>. Fourth, the fiscal burden at any
point depends on the <span class='ecti-1200'>stock </span>of active court orders, while our instrument is
constructed from the <span class='ecti-1200'>flow </span>of new case assignments. This is not a threat to
validity—the flow creates the stock incrementally, and persistent judge
assignments mean that flow-based shocks predict stock changes—but it
implies that effects may accumulate over time, motivating the dynamic
analysis in Section <a href='#dynamic-effects'>6.7<!-- tex4ht:ref: sec:dynamic  --></a>. We present balance tests and placebo outcomes in
Section <a href='#robustness-and-extensions'>9<!-- tex4ht:ref: sec:robustness  --></a>.
</p>
   <h4 class='subsectionHead' id='populationlevel-estimating-equations'><span class='titlemark'>5.3   </span> <a id='x1-240005.3'></a>Population-Level Estimating Equations</h4>
<!-- l. 250 --><p class='noindent'>Our main specification is a two-stage least squares (2SLS) model estimated at the
municipality-period level. The first stage relates judicial spending to the
                                                                          

                                                                          
instrument:
</p>
   <table class='equation'><tr><td>
   <div class='math-display'>
<img alt='             ¯       ′
Jmt =  α + δZmt +  X mtβ + γc + 𝜃t + 𝜀mt,
' class='math-display' src='main2x.png' /><a id='x1-24001r3'></a></div>
   </td><td class='equation-label'>(3)</td></tr></table>
<!-- l. 255 --><p class='nopar'>
where <span class='cmmi-12'>J</span><sub><span class='cmmi-8'>mt</span></sub> is per capita court-ordered health expenditure in municipality <span class='cmmi-12'>m </span>in
period <span class='cmmi-12'>t</span>, <span class='accentbar'><span class='cmmi-12'>Z</span></span><sub><span class='cmmi-8'>mt</span></sub> is the aggregated leave-one-out judge stringency instrument defined
in equation (<a href='#x1-23005r2'>2<!-- tex4ht:ref: eq:muni_instrument  --></a>), <span class='cmmi-12'>X</span><sub><span class='cmmi-8'>mt</span></sub> is a vector of time-varying municipality controls (log
population, income per capita, Gini coefficient, ESF coverage, and baseline health
spending per capita), <span class='cmmi-12'>γ</span><sub><span class='cmmi-8'>c</span></sub> are court fixed effects, <span class='cmmi-12'>𝜃</span><sub><span class='cmmi-8'>t</span></sub> are period fixed effects, and <span class='cmmi-12'>𝜀</span><sub><span class='cmmi-8'>mt</span></sub>
is the error term. The period is municipality-month for spending outcomes (which
are observed monthly in TCE-SP) and municipality-quarter or municipality-year
for health outcomes depending on cell-size requirements. The coefficient <span class='cmmi-12'>δ</span>
captures the first-stage relationship between judge leniency and judicial
spending.
</p><!-- l. 259 --><p class='indent'>   The second stage estimates the effect of judicial spending on health
                                                                          

                                                                          
outcomes:
</p>
   <table class='equation'><tr><td>
   <div class='math-display'>
<img alt='             ^       ′
Ymt =  α + τJmt +  Xmt β + γc + 𝜃t + νmt,
' class='math-display' src='main3x.png' /><a id='x1-24002r4'></a></div>
   </td><td class='equation-label'>(4)</td></tr></table>
<!-- l. 264 --><p class='nopar'>
where <span class='cmmi-12'>Y</span> <sub><span class='cmmi-8'>mt</span></sub> is a health outcome constructed from individual-level SIH or SIM
microdata—such as the rate of avoidable hospitalizations, cause-specific mortality,
or birth outcomes—and <span class='accentwidehat'><span class='cmmi-12'>J</span></span><sub><span class='cmmi-8'>mt</span></sub> is the predicted value from the first stage. For
population-level outcomes, <span class='cmmi-12'>Y</span> <sub><span class='cmmi-8'>mt</span></sub> includes all individuals residing in municipality <span class='cmmi-12'>m</span>,
including litigants. For non-litigant outcomes, we exclude individuals linked to
health lawsuits from SIH and SIM records before aggregating; the excluded
share is small, so non-litigant outcomes closely approximate population
measures. Comparing the two provides a first indication of whether effects
operate through direct benefits to litigants or spillovers to the broader
population.
</p><!-- l. 268 --><p class='indent'>   To compare the marginal product of judicial and administrative health
                                                                          

                                                                          
spending, we extend the specification to a two-endogenous-variable model:
</p>
   <table class='equation'><tr><td>
   <div class='math-display'>
<img alt='                               ′
Ymt =  α + τJ Jmt + τA Amt + Xmt β + γc + 𝜃t + νmt,
' class='math-display' src='main4x.png' /><a id='x1-24003r5'></a></div>
   </td><td class='equation-label'>(5)</td></tr></table>
<!-- l. 273 --><p class='nopar'>
where <span class='cmmi-12'>A</span><sub><span class='cmmi-8'>mt</span></sub> is per capita non-judicial (administrative) health spending and <span class='cmmi-12'>J</span><sub><span class='cmmi-8'>mt</span></sub> is
judicial spending as before. We instrument <span class='cmmi-12'>J</span><sub><span class='cmmi-8'>mt</span></sub> with judge leniency <span class='accentbar'><span class='cmmi-12'>Z</span></span><sub><span class='cmmi-8'>mt</span></sub> and <span class='cmmi-12'>A</span><sub><span class='cmmi-8'>mt</span></sub>
with plausibly exogenous variation in federal SUS transfers—specifically,
changes in per capita transfer allocations driven by formula revisions that
shift resources across municipalities within the same state and year. The
coefficients <span class='cmmi-12'>τ</span><sub><span class='cmmi-8'>J</span></sub> and <span class='cmmi-12'>τ</span><sub><span class='cmmi-8'>A</span></sub> are partial derivatives—the marginal health return to an
additional real of spending through each allocation channel, holding the
other constant. This reframes the comparison from “two LATEs from
separate regressions” to “two margins identified by orthogonal shifters
in a single equation.” The policy margins differ (judge leniency shifts
targeted pharmaceutical spending; transfer variation shifts programmatic
                                                                          

                                                                          
spending), so the comparison is informative about relative efficiency but does
not yield a clean welfare ranking without additional assumptions about
comparability.
</p><!-- l. 277 --><p class='indent'>   We include court fixed effects <span class='cmmi-12'>γ</span><sub><span class='cmmi-8'>c</span></sub> throughout, so that identification comes from
variation in judge stringency within courts. Period fixed effects <span class='cmmi-12'>𝜃</span><sub><span class='cmmi-8'>t</span></sub> absorb
common time trends. Standard errors are clustered at the court (<span class='ecti-1200'>vara</span>)
level—the unit within which judges are randomly assigned; we assess
robustness to alternative clustering (municipality, court-year, two-way) in
Section <a href='#robustness-and-extensions'>9<!-- tex4ht:ref: sec:robustness  --></a>.
</p><!-- l. 279 --><p class='indent'>   Our 2SLS identifies the effect of spending changes induced by judicial
discretion at the margin—the policy-relevant margin for reforms that
tighten or relax granting standards. Because we use a single aggregated
instrument rather than individual judge indicators, the specification avoids
many-instruments bias (<a id='x1-24004'></a>Bhuller et al., <a href='#cite.0@bhuller2020'>2020</a>). We report the first-stage
<span class='cmmi-12'>F</span>-statistic throughout and assess robustness to alternative constructions of the
instrument.
</p><!-- l. 281 --><p class='indent'>   The estimand <span class='cmmi-12'>τ </span>is a weighted average of marginal effects per real of judicial
spending, where the weights reflect how judge assignment moves spending across
case types (on-formulary versus off-formulary, drugs versus procedures,
high-volume-attorney versus Defensoria cases). It captures the municipality-wide
effect, bundling direct benefits to litigants, indirect spillovers through crowd-out,
and composition shifts in the health budget. The complier municipalities are those
whose judicial spending is responsive to the leniency of assigned judges—plausibly
municipalities with many borderline cases and substantial judge-level variance in
stringency. We decompose the first stage by case type to characterize which
                                                                          

                                                                          
margins drive spending variation. We report specifications both with and
without controlling for the number of health cases filed (<span class='cmmi-12'>n</span><sub><span class='cmmi-8'>mt</span></sub>); because filing
volume may itself respond to perceived judicial leniency, conditioning
on <span class='cmmi-12'>n</span><sub><span class='cmmi-8'>mt</span></sub> risks post-treatment bias, so our preferred specification excludes
it.<span class='footnote-mark'><a href='main16.html#fn15x0'><sup class='textsuperscript'>15</sup></a></span><a id='x1-24005f15'></a> 
</p>
   <h4 class='subsectionHead' id='litigantlevel-estimating-equations'><span class='titlemark'>5.4   </span> <a id='x1-250005.4'></a>Litigant-Level Estimating Equations</h4>
<!-- l. 286 --><p class='noindent'>To estimate the direct effect of winning a health lawsuit on litigant outcomes, we
exploit case-level random judge assignment. The unit of analysis is a plaintiff <span class='cmmi-12'>i</span>
observed in a panel around the filing date. The first stage relates the grant
decision to judge leniency:
</p>
   <table class='equation'><tr><td>
   <div class='math-display'>
<img alt='                       ′
Dijct = α + π Zijct + W itβ + ϕct + ηijct,
' class='math-display' src='main5x.png' /><a id='x1-25001r6'></a></div>
   </td><td class='equation-label'>(6)</td></tr></table>
<!-- l. 291 --><p class='nopar'>
where <span class='cmmi-12'>D</span><sub><span class='cmmi-8'>ijct</span></sub> is an indicator (or a measure of the cost) of granting the
request for plaintiff <span class='cmmi-12'>i </span>assigned to judge <span class='cmmi-12'>j </span>in court <span class='cmmi-12'>c </span>at time <span class='cmmi-12'>t</span>, <span class='cmmi-12'>Z</span><sub><span class='cmmi-8'>ijct</span></sub> is the
leave-one-out judge leniency measure defined in equation (<a href='#x1-23004r1'>1<!-- tex4ht:ref: eq:instrument  --></a>), <span class='cmmi-12'>W</span><sub><span class='cmmi-8'>it</span></sub> are
plaintiff-level controls (age, sex, case type), and <span class='cmmi-12'>ϕ</span><sub><span class='cmmi-8'>ct</span></sub> are court-by-filing-period fixed
effects.
</p><!-- l. 295 --><p class='indent'>   The second stage estimates the effect on post-filing outcomes:
</p>
   <table class='equation'><tr><td>
   <div class='math-display'>
<img alt='                       ′
Yi,t+s = α + λ ^Dijct + W itβ + ϕct + νijct,
' class='math-display' src='main6x.png' /><a id='x1-25002r7'></a></div>
   </td><td class='equation-label'>(7)</td></tr></table>
<!-- l. 300 --><p class='nopar'>
where <span class='cmmi-12'>Y</span> <sub><span class='cmmi-8'>i,t</span><span class='cmr-8'>+</span><span class='cmmi-8'>s</span></sub> is a health or labor-market outcome for plaintiff <span class='cmmi-12'>i </span>measured <span class='cmmi-12'>s </span>periods
                                                                          

                                                                          
after filing—such as hospitalization, mortality, or earnings in RAIS—and <span class='accentwidehat'><span class='cmmi-12'>D</span></span><sub><span class='cmmi-8'>ijct</span></sub> is
the predicted grant from the first stage. The parameter <span class='cmmi-12'>λ </span>identifies the causal
effect of a favorable judicial decision on litigant outcomes, for the subpopulation
of marginal cases (compliers whose grant status is determined by judge leniency).
We vary <span class='cmmi-12'>s </span>to trace event-study dynamics, including pre-filing periods as a placebo
check.
</p><!-- l. 304 --><p class='indent'>   Standard errors are clustered at the judge level, the unit of random
assignment in the case-level design. We present results both unweighted and
reweighted by inverse probability of name linkage (IPW) to account for the
selection induced by restricting to litigants with nationally unique names
(Section <a href='#sample-construction-and-limitations'>4.5<!-- tex4ht:ref: sec:sample  --></a>).
</p><!-- l. 306 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='decomposition'><span class='titlemark'>5.5   </span> <a id='x1-260005.5'></a>Decomposition</h4>
<!-- l. 309 --><p class='noindent'>The population-level estimate <span class='cmmi-12'>τ </span>from equation (<a href='#x1-24002r4'>4<!-- tex4ht:ref: eq:secondstage  --></a>) reflects a weighted average of
direct effects on litigants and spillovers to non-litigants:
</p>
   <table class='equation'><tr><td>
   <div class='math-display'>
                                                                          

                                                                          
<img alt='        L           NL
τ ≈  ωτ  +  (1 − ω )τ  ,
' class='math-display' src='main7x.png' /><a id='x1-26001r8'></a></div>
   </td><td class='equation-label'>(8)</td></tr></table>
<!-- l. 314 --><p class='nopar'>
where <span class='cmmi-12'>τ</span><sup><span class='cmmi-8'>L</span></sup> is the per capita effect on litigants (recoverable from the case-level
estimates in Section <a href='#litigantlevel-estimating-equations'>5.4<!-- tex4ht:ref: sec:litigant_equations  --></a>, scaled by the litigant share of the population), <span class='cmmi-12'>τ</span><sup><span class='cmmi-8'>NL</span></sup> is
the per capita effect on non-litigants (estimated using the non-litigant outcome
specification), and <span class='cmmi-12'>ω </span>is the litigant population share. This decomposition connects
the two tiers of the analysis. Several sign combinations are informative: <span class='cmmi-12'>τ</span><sup><span class='cmmi-8'>L</span></sup> <span class='cmmi-12'>&gt; </span><span class='cmr-12'>0</span>
with <span class='cmmi-12'>τ</span><sup><span class='cmmi-8'>NL</span></sup> <span class='cmmi-12'>&lt; </span><span class='cmr-12'>0 </span>is consistent with the distortionary view (courts benefit litigants at
the expense of crowd-out); <span class='cmmi-12'>τ</span><sup><span class='cmmi-8'>L</span></sup> <span class='cmmi-12'>&gt; </span><span class='cmr-12'>0 </span>with <span class='cmmi-12'>τ</span><sup><span class='cmmi-8'>NL</span></sup> <span class='cmsy-10x-x-120'>≥ </span><span class='cmr-12'>0 </span>favors the corrective
view (courts improve delivery without harming others); and <span class='cmmi-12'>τ</span><sup><span class='cmmi-8'>L</span></sup> <span class='cmsy-10x-x-120'>≤ </span><span class='cmr-12'>0 </span>with
<span class='cmmi-12'>τ</span><sup><span class='cmmi-8'>NL</span></sup> <span class='cmmi-12'>&lt; </span><span class='cmr-12'>0 </span>would suggest that judicial mandates are welfare-reducing even
for the targeted population. The decomposition connects to the three
predictions in Section <a href='#empirical-strategy'>5<!-- tex4ht:ref: sec:strategy  --></a> and disciplines the interpretation of the aggregate
estimate.
</p><!-- l. 319 --><p class='noindent'>
</p>
   <h3 class='sectionHead' id='effects-on-health-outcomes'><span class='titlemark'>6   </span> <a id='x1-270006'></a>Effects on Health Outcomes</h3>
<!-- l. 322 --><p class='noindent'>This section presents the main results in two tiers: population-level effects of
                                                                          

                                                                          
judicial spending on health outcomes (Sections <a href='#first-stage'>6.1<!-- tex4ht:ref: sec:firststage  --></a>–<a href='#nonlitigant-effects'>6.3<!-- tex4ht:ref: sec:nonlitigant  --></a>), and direct effects on
litigants (Section <a href='#direct-effects-on-litigants'>6.4<!-- tex4ht:ref: sec:litigant_results  --></a>). We then decompose the aggregate estimate (Section <a href='#decomposition-direct-benefits-versus-crowdout'>6.5<!-- tex4ht:ref: sec:decomposition_results  --></a>),
compare returns across allocation channels (Section <a href='#comparing-returns-courts-versus-administrative-allocation'>6.6<!-- tex4ht:ref: sec:returns_comparison  --></a>), and examine dynamic
effects (Section <a href='#dynamic-effects'>6.7<!-- tex4ht:ref: sec:dynamic  --></a>). Our primary outcomes are avoidable hospitalizations
(ICSAP), infant mortality, and mean birth weight; all other outcomes are treated
as secondary or exploratory, and we adjust for multiple testing across the primary
set.
</p><!-- l. 324 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='first-stage'><span class='titlemark'>6.1   </span> <a id='x1-280006.1'></a>First Stage</h4>
<!-- l. 327 --><p class='noindent'>Table <span class='ecbx-1200'>??</span> reports estimates of equation (<a href='#x1-24001r3'>3<!-- tex4ht:ref: eq:firststage  --></a>). The dependent variable is per capita
court-mandated health spending in municipality <span class='cmmi-12'>m </span>in period <span class='cmmi-12'>t</span>. The key regressor
is the aggregated leave-one-out judge stringency measure <span class='accentbar'><span class='cmmi-12'>Z</span></span><sub><span class='cmmi-8'>mt</span></sub>. We report
specifications with progressively richer controls: column (1) includes court
and period fixed effects only; column (2) adds time-varying municipality
characteristics; column (3) adds court-by-period fixed effects. We present
first-stage results at both the municipality-year and municipality-month
levels.
</p><!-- l. 335 --><p class='indent'>   Across specifications, municipalities whose health cases are assigned to more
lenient judges experience significantly higher judicial health spending. The
first-stage <span class='cmmi-12'>F</span>-statistic exceeds conventional thresholds for instrument strength,
confirming that judge stringency is a powerful predictor of judicial spending at the
municipality level.
                                                                          

                                                                          
</p><!-- l. 337 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='population-health-effects'><span class='titlemark'>6.2   </span> <a id='x1-290006.2'></a>Population Health Effects</h4>
<!-- l. 340 --><p class='noindent'>Table <span class='ecbx-1200'>??</span> presents the 2SLS estimates of equation (<a href='#x1-24002r4'>4<!-- tex4ht:ref: eq:secondstage  --></a>). Each column reports the
effect of a one-unit increase in per capita judicial health spending on a different
health outcome, constructed from individual-level SIH and SIM microdata
aggregated to the municipality-period level. Panel A reports results for mortality
outcomes (infant mortality rate, under-five mortality, amenable mortality by
cause). Panel B reports results for hospitalizations (total hospitalization rate,
avoidable hospitalizations decomposed by ICSAP condition family). Panel C
reports results for birth outcomes (mean birth weight, incidence of low birth
weight, preterm birth rate).
</p><!-- l. 349 --><p class='indent'>   For comparison, we report the OLS estimates alongside the 2SLS estimates. If
judicial spending is positively correlated with unobserved health needs—as we
would expect if sicker populations generate more litigation—then OLS estimates
of <span class='cmmi-12'>τ </span>will be biased toward finding that judicial spending worsens health outcomes
(or, equivalently, biased against finding health improvements). A comparison of
the OLS and 2SLS estimates thus provides a diagnostic for the direction and
magnitude of endogeneity bias.
</p><!-- l. 351 --><p class='indent'>   The reduced-form estimates—regressing health outcomes directly on the
instrument <span class='accentbar'><span class='cmmi-12'>Z</span></span><sub><span class='cmmi-8'>mt</span></sub>—provide a model-free assessment of whether judge stringency
affects population health. Because the reduced form does not depend on
the first-stage functional form, it offers a transparent check on the main
                                                                          

                                                                          
results.
</p><!-- l. 353 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='nonlitigant-effects'><span class='titlemark'>6.3   </span> <a id='x1-300006.3'></a>Non-Litigant Effects</h4>
<!-- l. 356 --><p class='noindent'>To isolate spillovers to the non-litigating population, we re-estimate equation (<a href='#x1-24002r4'>4<!-- tex4ht:ref: eq:secondstage  --></a>)
using outcomes that exclude linked litigants from the SIH and SIM microdata
before aggregation to the municipality-period level. Because litigants are a small
share of total hospitalizations and deaths in any municipality-period, the
non-litigant outcomes closely approximate the population-level measures, and any
difference between the two indicates the contribution of direct litigant effects to
the aggregate estimate.
</p><!-- l. 362 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='direct-effects-on-litigants'><span class='titlemark'>6.4   </span> <a id='x1-310006.4'></a>Direct Effects on Litigants</h4>
<!-- l. 365 --><p class='noindent'>Table <span class='ecbx-1200'>??</span> presents the 2SLS estimates of equation (<a href='#x1-25002r7'>7<!-- tex4ht:ref: eq:litigant_secondstage  --></a>), using the case-level judge
leniency instrument. The sample is the plaintiff-by-period panel constructed from
linked litigants. The endogenous variable is a grant indicator (or the granted
cost). We report effects on post-filing hospitalization, mortality, and earnings in
RAIS. Event-study figures trace effects from 12 months before filing (as a
pre-trends check) through 36 months after.
</p><!-- l. 379 --><p class='indent'>   Court-by-filing-period fixed effects ensure that identification comes from
                                                                          

                                                                          
within-court variation in judge leniency. Standard errors are clustered at the judge
level. We present both unweighted estimates and IPW-reweighted estimates that
adjust for the selection induced by name-linkage restrictions.
</p><!-- l. 381 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='decomposition-direct-benefits-versus-crowdout'><span class='titlemark'>6.5   </span> <a id='x1-320006.5'></a>Decomposition: Direct Benefits versus Crowd-Out</h4>
<!-- l. 384 --><p class='noindent'>We interpret the population, non-litigant, and litigant estimates jointly using the
decomposition in equation (<a href='#x1-26001r8'>8<!-- tex4ht:ref: eq:decomposition  --></a>). The key question is whether the aggregate
population effect <span class='cmmi-12'>τ </span>reflects direct benefits to litigants, spillovers (positive or
negative) to non-litigants, or both. Several sign combinations are possible. If
litigant effects are positive but the population effect is zero or negative, the
implied non-litigant effect is negative—consistent with crowd-out. If both
litigant and non-litigant effects are positive, courts improve health broadly,
consistent with the corrective view. We report the implied decomposition with
confidence intervals obtained by bootstrapping jointly across the two
tiers.
</p><!-- l. 393 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='comparing-returns-courts-versus-administrative-allocation'><span class='titlemark'>6.6   </span> <a id='x1-330006.6'></a>Comparing Returns: Courts versus Administrative Allocation</h4>
<!-- l. 396 --><p class='noindent'>Table <span class='ecbx-1200'>??</span> reports three numbers for each outcome: (i) the marginal product
of judicial spending (from the judge IV), (ii) the marginal product of
                                                                          

                                                                          
administrative spending (from the transfer IV in equation (<a href='#x1-24003r5'>5<!-- tex4ht:ref: eq:twoendo  --></a>)), and (iii) the
non-litigant-only judge effect, which provides the cleanest “courts versus
bureaucracies” comparison by stripping out direct litigant benefits. We
translate estimates into cost-effectiveness metrics: deaths averted and
ICSAP hospitalizations averted per R$ million of spending through each
channel.
</p><!-- l. 406 --><p class='indent'>   The two instruments identify effects at different policy margins: judge leniency
shifts targeted pharmaceutical spending subject to procurement premia, while
transfer variation shifts programmatic spending through a fiscal federalism
channel. The two-endogenous-variable model (equation <a href='#x1-24003r5'>5<!-- tex4ht:ref: eq:twoendo  --></a>) addresses this by
estimating both partial derivatives simultaneously, but the comparison
remains informative about relative efficiency only under the assumption that
the two spending channels affect health through distinct and separable
mechanisms.
</p><!-- l. 408 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='dynamic-effects'><span class='titlemark'>6.7   </span> <a id='x1-340006.7'></a>Dynamic Effects</h4>
<!-- l. 411 --><p class='noindent'>To examine the timing of effects, we estimate event-study specifications at both
tiers. At the municipality level, we allow the effect of judicial spending to vary
with the lag between the period of judge assignment and the period of health
outcome measurement. This tests whether effects emerge immediately (consistent
with direct health gains from court-ordered treatments) or with a delay
(consistent with crowding out of preventive services that affects health with a lag,
                                                                          

                                                                          
and with the accumulation of ongoing mandates that leave municipal budgets
increasingly rigid). At the litigant level, the event-study figures from Section <a href='#direct-effects-on-litigants'>6.4<!-- tex4ht:ref: sec:litigant_results  --></a>
trace the trajectory of individual health and earnings relative to filing
date.
</p><!-- l. 418 --><p class='indent'>   The event-study estimates also serve as a pre-trends check: effects in periods
before the judicial spending shock should be close to zero if the instrument is
valid.
</p><!-- l. 421 --><p class='noindent'>
</p>
   <h3 class='sectionHead' id='who-benefits-distributional-incidence'><span class='titlemark'>7   </span> <a id='x1-350007'></a>Who Benefits? Distributional Incidence</h3>
<!-- l. 424 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='who-are-the-litigants'><span class='titlemark'>7.1   </span> <a id='x1-360007.1'></a>Who Are the Litigants?</h4>
<!-- l. 426 --><p class='noindent'>Before examining distributional effects, we characterize the population of health
litigants. Table <span class='ecbx-1200'>??</span> compares litigants linked to RAIS and CadÚnico with the
general population in their municipality along several dimensions: formal
employment status, average earnings (from RAIS), earnings trajectory in the
years before filing, participation in Bolsa Família and other social programs,
CadÚnico registration, and age. Because RAIS covers the universe of
formal employment relationships, we can characterize not just the average
litigant but the full earnings distribution—including the shares below the
                                                                          

                                                                          
minimum wage, between one and three minimum wages, and above three
minimum wages—and compare it to the population distribution in the same
municipality-year.
</p><!-- l. 435 --><p class='indent'>   This descriptive analysis speaks to a central question in the literature: whether
health litigation is a tool of the relatively advantaged or whether it reaches
disadvantaged populations. The answer may differ across court systems (TJSP
versus TRF3) and over time, as the Defensoria Pública has expanded its role in
health litigation.
</p><!-- l. 437 --><p class='indent'>   A notable gap in the existing literature is the absence of racial disaggregation.
Despite Brazil’s mandatory race/color reporting in health records and the
well-documented racial stratification of SUS dependence—approximately
two-thirds of SUS users identify as Black or <span class='ecti-1200'>pardo </span>(mixed-race)—no study of
health litigation reports the race of litigants. The circumstantial evidence suggests
under-representation: litigants are disproportionately drawn from wealthier,
lower-vulnerability neighborhoods, represented by private attorneys, and
hold prescriptions from private providers—all characteristics inversely
correlated with being Black or <span class='ecti-1200'>pardo </span>in Brazil (<a id='x1-36001'></a>Chieffi &amp; Barata, <a href='#cite.0@chieffi2009csp'>2009</a><a id='x1-36002'></a>; Ferraz,
<a href='#cite.0@ferraz2009hhr'>2009</a>). Our linked administrative data allow us to examine this dimension
directly.
</p><!-- l. 439 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='heterogeneous-effects-by-municipality-characteristics'><span class='titlemark'>7.2   </span> <a id='x1-370007.2'></a>Heterogeneous Effects by Municipality Characteristics</h4>
<!-- l. 441 --><p class='noindent'>We next examine whether the health effects of judicial spending differ across
                                                                          

                                                                          
municipalities with different baseline characteristics. We split the sample
along several dimensions: municipality income (above versus below the
median), inequality (Gini coefficient), the share of the population enrolled
in CadÚnico, and the presence of a Defensoria Pública office. Three
additional splits are designed to discriminate between the corrective and
distortionary views introduced in Section <a href='#empirical-strategy'>5<!-- tex4ht:ref: sec:strategy  --></a>. First, baseline health system
capacity (ESF coverage) tests whether courts are most beneficial where
administrative delivery is weakest. Second, fiscal capacity (own-source revenue
share) tests whether vertical fiscal mismatch amplifies the costs of court
mandates. Third, the on-formulary versus off-formulary composition of
judicial demand provides a direct discriminator: on-formulary mandates
correct administrative delivery failures, while off-formulary mandates
impose new obligations relative to the administratively defined benefit
package.
</p><!-- l. 443 --><p class='indent'>   The Defensoria split exploits dramatic variation in access to public legal
representation: as of 2013, public defenders were absent from 72 percent of
Brazilian comarcas (<a id='x1-37001'></a>Instituto de Pesquisa Econômica Aplicada &amp; Associação
Nacional dos Defensores Públicos, <a href='#cite.0@ipea_anadep2013'>2013</a>). Defensoria presence is associated with a
seven-fold increase in the probability of health litigation (<a id='x1-37002'></a>Biehl et al., <a href='#cite.0@biehl2015csp'>2015</a>),
suggesting that legal access—not health need alone—shapes the geography of
lawsuits. Municipalities with a Defensoria have a different composition of litigants
(more low-income, publicly represented) than those without, allowing us
to test whether the health effects of judicial spending depend on who
litigates. In the framework of <a id='x1-37003'></a>Galanter (<a href='#cite.0@galanter1974lsr'>1974</a>), the Defensoria functions as a
repeat-player institution that lowers per-case costs for disadvantaged litigants,
                                                                          

                                                                          
potentially altering both the volume and the health return of judicial
spending.
</p><!-- l. 454 --><p class='indent'>   If judicial spending improves health outcomes primarily in municipalities that
are already well-resourced, then judicialization reinforces existing inequalities.
Conversely, if effects are concentrated in poorer municipalities—perhaps because
court orders correct larger deficiencies in public provision—then judicialization
may be equalizing.
</p><!-- l. 456 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='effects-on-disadvantaged-populations'><span class='titlemark'>7.3   </span> <a id='x1-380007.3'></a>Effects on Disadvantaged Populations</h4>
<!-- l. 458 --><p class='noindent'>We complement the municipality-level heterogeneity analysis with an examination
of outcomes that disproportionately affect disadvantaged populations.
Individual-level SIH and SIM microdata enable stratification by age group,
cause of admission or death, and proxies for SUS dependence. Avoidable
hospitalizations (ICSAP) are concentrated among low-income populations who
rely on primary care through SUS; we decompose these by condition family
(cardiovascular, respiratory, infectious) and urgency to identify which conditions
drive the aggregate effect. Infant mortality and amenable mortality by
age provide additional margins where crowd-out of primary care should
be most visible. Because SIH records the patient’s municipality, we can
construct age- and sex-standardized rates at the municipality-period level,
avoiding the ecological fallacy that arises from using only municipality-year
aggregates.
                                                                          

                                                                          
</p><!-- l. 468 --><p class='noindent'>
</p>
   <h3 class='sectionHead' id='mechanisms-and-budgetary-tradeoffs'><span class='titlemark'>8   </span> <a id='x1-390008'></a>Mechanisms and Budgetary Trade-offs</h3>
<!-- l. 471 --><p class='noindent'>The aggregate health effects documented in Section <a href='#effects-on-health-outcomes'>6<!-- tex4ht:ref: sec:outcomes  --></a> reflect both the
direct benefits of court-ordered treatments for litigants and the indirect
costs of displacing other health spending. This section investigates the
budgetary mechanisms through which judicial spending affects population
health.
</p><!-- l. 473 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='effects-on-the-composition-of-municipal-health-spending'><span class='titlemark'>8.1   </span> <a id='x1-400008.1'></a>Effects on the Composition of Municipal Health Spending</h4>
<!-- l. 475 --><p class='noindent'>We estimate the effect of judicial spending on the composition of municipal health
budgets using subfunction categories as outcomes. Specifically, we replace <span class='cmmi-12'>Y</span> <sub><span class='cmmi-8'>mt</span></sub> in
equation (<a href='#x1-24002r4'>4<!-- tex4ht:ref: eq:secondstage  --></a>) with per capita spending on each health subfunction: Primary Care
(301), Hospital and Outpatient Care (302), Pharmaceutical and Therapeutic
Support (303), Health Surveillance (304), Epidemiological Surveillance (305), and
administrative costs.
</p><!-- l. 482 --><p class='indent'>   A key question is whether court-mandated spending increases the total
municipal health budget or merely reallocates within it. If the coefficient on
judicial spending is close to one when total health spending is the dependent
variable, court orders primarily add to the budget (e.g., through emergency
                                                                          

                                                                          
appropriations or deficit spending). If the coefficient is close to zero, court orders
are absorbed through reallocation, with other programs shrinking by a
corresponding amount.
</p><!-- l. 484 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='crowding-out-of-primary-care'><span class='titlemark'>8.2   </span> <a id='x1-410008.2'></a>Crowding Out of Primary Care</h4>
<!-- l. 486 --><p class='noindent'>We test directly for crowding out of primary care by examining whether
judicial spending affects ESF coverage (the number of active Family Health
Strategy teams per capita), vaccination rates, and the quality of prenatal
care (measured by the share of births with adequate prenatal visits in
SINASC).
</p><!-- l. 492 --><p class='indent'>   These outcomes are important because primary care and preventive services
have high average returns to population health (<a id='x1-41001'></a>Macinko et al., <a href='#cite.0@macinko2006jech'>2006</a>), and their
disruption could generate negative spillovers that offset the direct health gains
from court-ordered treatments.
</p><!-- l. 494 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='effects-on-hospital-utilization'><span class='titlemark'>8.3   </span> <a id='x1-420008.3'></a>Effects on Hospital Utilization</h4>
<!-- l. 496 --><p class='noindent'>Finally, we examine whether judicial spending affects hospital capacity and
utilization patterns. Court orders may generate demand for hospitalizations (e.g.,
court-ordered surgeries or chemotherapy) while simultaneously reducing the
                                                                          

                                                                          
resources available for other hospital services. Individual-level SIH microdata
enable decomposition by ICD-10 diagnosis group, procedure type, and
urgency classification. We decompose the hospitalization effects along three
margins: elective versus emergency admissions, ICSAP condition families
(cardiovascular, respiratory, infectious, diabetes-related), and high-cost
versus routine procedures. This granularity distinguishes crowd-out of
primary-care-sensitive conditions from shifts in hospital case mix driven by
court-ordered treatments.
</p><!-- l. 504 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='supplyside-drivers-lawyer-concentration-and-pharmaceutical-networks'><span class='titlemark'>8.4   </span> <a id='x1-430008.4'></a>Supply-Side Drivers: Lawyer Concentration and Pharmaceutical
Networks</h4>
<!-- l. 507 --><p class='noindent'>A growing body of evidence suggests that a substantial share of health litigation is
supply-driven: organized networks of lawyers, physicians, and pharmaceutical
firms generate cases as a channel for market access, a form of supplier-induced
demand (<a id='x1-43001'></a>Arrow, <a href='#cite.0@arrow1963aer'>1963</a><a id='x1-43002'></a>; McGuire, <a href='#cite.0@mcguire2000hhe'>2000</a>). In São Paulo, just 19 lawyers filed 63
percent of 2,927 health cases studied in 2006, with concentration highest for
expensive drugs not yet incorporated into SUS (<a id='x1-43003'></a>Chieffi &amp; Barata, <a href='#cite.0@chieffibarata2010rsp'>2010</a>). Criminal
investigations have uncovered fraud networks involving pharmaceutical
laboratories, patient associations, and law firms—in one case defrauding R$63
million from state coffers through fabricated lawsuits (see<a id='x1-43004'></a> Soares &amp; Deprá, <a href='#cite.0@soaresdepra2012physis'>2012</a>,
and Appendix <a href='#supplyside-case-studies'>C<!-- tex4ht:ref: sec:supplyside_appendix  --></a> for details). Manufacturers also game the health technology
assessment process: firms with weak evidence bypass CONITEC evaluation
                                                                          

                                                                          
and pursue the judicial channel, where grant rates exceed 80 percent
(<a id='x1-43005'></a>Tamachiro et al., <a href='#cite.0@tamachiro2022csp'>2022</a>). If supply-driven cases have lower health returns than
demand-driven ones, the marginal cases induced by lenient judges—which may be
disproportionately supply-side—will drag down the average return to judicial
spending.
</p><!-- l. 509 --><p class='indent'>   We probe this by splitting cases according to the concentration of legal
representation: cases filed by high-volume lawyers (attorneys exceeding a
threshold number of health cases per year) versus those filed by low-volume or
Defensoria Pública attorneys. If the efficiency costs of judicialization are
concentrated in the supply-driven segment, the estimated effect of judge leniency
on health outcomes should differ across these subsamples, with stronger negative
effects in the high-volume-lawyer group.
</p><!-- l. 517 --><p class='noindent'>
</p>
   <h3 class='sectionHead' id='robustness-and-extensions'><span class='titlemark'>9   </span> <a id='x1-440009'></a>Robustness and Extensions</h3>
<!-- l. 520 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='balance-tests'><span class='titlemark'>9.1   </span> <a id='x1-450009.1'></a>Balance Tests</h4>
<!-- l. 522 --><p class='noindent'>If cases are randomly assigned to judges within courts, the instrument <span class='accentbar'><span class='cmmi-12'>Z</span></span><sub><span class='cmmi-8'>mt</span></sub> should
be uncorrelated with predetermined municipality characteristics after conditioning
on court and year fixed effects. Table <span class='ecbx-1200'>??</span> regresses the instrument on a range of
                                                                          

                                                                          
baseline municipality characteristics measured prior to our sample period:
population, income per capita, Gini coefficient, ESF coverage, health spending per
capita, and baseline health outcomes.
</p><!-- l. 529 --><p class='indent'>   We also test for balance in case characteristics. Conditional on court and year
fixed effects, cases assigned to more lenient judges should not differ systematically
in diagnosis severity, plaintiff demographics, or the type of treatment
requested.
</p><!-- l. 531 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='alternative-instrument-constructions'><span class='titlemark'>9.2   </span> <a id='x1-460009.2'></a>Alternative Instrument Constructions</h4>
<!-- l. 533 --><p class='noindent'>We assess the sensitivity of our results to the construction of the instrument.
Specifically, we examine: (i) using the judge’s grant rate rather than the cost
of granted treatments; (ii) varying the leave-out window (leave-one-out
versus leave-year-out versus leave-municipality-out); (iii) residualizing the
instrument by case characteristics before aggregation; and (iv) restricting the
instrument to judges with a minimum caseload to reduce small-sample
noise.
</p><!-- l. 539 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='placebo-tests'><span class='titlemark'>9.3   </span> <a id='x1-470009.3'></a>Placebo Tests</h4>
<!-- l. 541 --><p class='noindent'>We conduct placebo tests using outcomes that should not respond to judicial
                                                                          

                                                                          
health spending. These include non-health municipal outcomes such as
educational attainment, crime rates, and economic activity (measured by
nightlight intensity or formal employment). A significant effect on placebo
outcomes would raise concerns about the exclusion restriction.
</p><!-- l. 547 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='sensitivity-checks'><span class='titlemark'>9.4   </span> <a id='x1-480009.4'></a>Sensitivity Checks</h4>
<!-- l. 549 --><p class='noindent'>We examine the robustness of the main results to alternative sample definitions
and estimation choices: restricting the sample to different time periods; varying
the level of clustering (court versus municipality versus court-year); dropping
municipalities with very few health cases; and estimating the model separately for
TJSP and TRF3 cases.
</p><!-- l. 555 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='monotonicity'><span class='titlemark'>9.5   </span> <a id='x1-490009.5'></a>Monotonicity</h4>
<!-- l. 557 --><p class='noindent'>We provide evidence on the monotonicity assumption by testing whether judge
stringency is consistent across case types. Specifically, we split health cases by
treatment category (medicines, procedures, hospital care) and by case
characteristics (on-list versus off-list medicines, cases with Defensoria
representation versus private attorneys). If the same judges are consistently
lenient or strict across these subgroups, this supports monotonicity.
                                                                          

                                                                          
</p><!-- l. 563 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='namelinkage-selection'><span class='titlemark'>9.6   </span> <a id='x1-500009.6'></a>Name-Linkage Selection</h4>
<!-- l. 565 --><p class='noindent'>The litigant-level analysis restricts to plaintiffs with nationally unique names,
introducing potential selection. We assess this in three ways. First, we report a
selection table comparing linked and unlinked litigants on case characteristics
(court, filing year, grant rate, case type, attorney type, municipality of origin).
Second, we present IPW-reweighted estimates, where the inverse probability
weights are based on a model of linkage probability conditional on observables.
Third, we stratify results by quintiles of the predicted name-uniqueness propensity
to assess whether treatment effects vary systematically with the likelihood of
being linked. If IPW-reweighted and unweighted estimates are similar, selection
on observables is unlikely to substantially bias the litigant-level results. We note
that name-linkage selection affects external validity (which litigants are
represented) but not internal validity (the IV remains valid for the linked
subsample).
</p><!-- l. 572 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='inference-robustness'><span class='titlemark'>9.7   </span> <a id='x1-510009.7'></a>Inference Robustness</h4>
<!-- l. 574 --><p class='noindent'>We assess the sensitivity of inference to alternative clustering and weighting
choices. For population-level specifications, we compare standard errors
                                                                          

                                                                          
clustered at the court (<span class='ecti-1200'>vara</span>) level (baseline), the municipality level, and
two-way clustering by court and municipality. For litigant-level specifications,
we compare clustering at the judge level (baseline) and the court level.
We also report municipality-population-weighted estimates alongside the
unweighted baseline, since large municipalities contribute disproportionately to
aggregate health outcomes but may respond differently to judicial spending
shocks.
</p><!-- l. 582 --><p class='noindent'>
</p>
   <h3 class='sectionHead' id='discussion-and-policy-implications'><span class='titlemark'>10   </span> <a id='x1-5200010'></a>Discussion and Policy Implications</h3>
<!-- l. 585 --><p class='noindent'>We use the conceptual framework in Section <a href='#empirical-strategy'>5<!-- tex4ht:ref: sec:strategy  --></a> to interpret the estimates and
draw implications for the design of institutions that allocate spending ex post.
The discussion is organized around the three predictions developed in
Section <a href='#empirical-strategy'>5<!-- tex4ht:ref: sec:strategy  --></a>.
</p><!-- l. 587 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='efficiency'><span class='titlemark'>10.1   </span> <a id='x1-5300010.1'></a>Efficiency</h4>
<!-- l. 589 --><p class='noindent'>Prediction 1 states that court mandates shift spending from programmatic
categories toward pharmaceutical and therapeutic spending, with displacement
amplified by the procurement premium. Our 2SLS estimates of <span class='cmmi-12'>τ </span>in equation (<a href='#x1-24002r4'>4<!-- tex4ht:ref: eq:secondstage  --></a>)
measure the health return to a marginal real of court-mandated spending. The
                                                                          

                                                                          
comparison with administrative spending returns (Section <a href='#effects-on-health-outcomes'>6<!-- tex4ht:ref: sec:outcomes  --></a>) provides an
informative benchmark, though the two instruments identify different local
average treatment effects—judge leniency shifts targeted pharmaceutical
spending, while transfer variation shifts total programmatic spending—so the
comparison speaks to relative efficiency only under additional assumptions about
the comparability of these margins.
</p><!-- l. 597 --><p class='indent'>   The efficiency interpretation hinges on what gets displaced. If judicial orders
primarily crowd out epidemiological surveillance or health administration, even
modest returns to judicial spending imply efficiency gains. If instead they displace
primary care and prevention, the threshold is correspondingly higher. Our
subfunction-level budget data will allow us to distinguish these cases
directly.
</p><!-- l. 599 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='distributional-incidence'><span class='titlemark'>10.2   </span> <a id='x1-5400010.2'></a>Distributional Incidence</h4>
<!-- l. 601 --><p class='noindent'>Prediction 3 states that if litigation access is positively correlated with income,
court mandates transfer resources from the general population to a selected
subpopulation of litigants. The distributional analysis in Section <a href='#who-benefits-distributional-incidence'>7<!-- tex4ht:ref: sec:equity  --></a> tests this by
examining two margins: who litigates (direct beneficiaries) and whose care is
displaced (indirect costs of crowding out).
</p><!-- l. 608 --><p class='indent'>   Even if litigants are predominantly disadvantaged—as some studies suggest
(<a id='x1-54001'></a>Biehl et al., <a href='#cite.0@biehl2012hhr'>2012</a>)—the net distributional effect could be regressive if crowding
out disproportionately harms the poorest populations who depend on
                                                                          

                                                                          
primary care. Conversely, if litigants are relatively advantaged (<a id='x1-54002'></a>Ferraz,
<a href='#cite.0@ferraz2009hhr'>2009</a>), but judicial spending creates positive spillovers (e.g., by forcing
municipalities to increase total health budgets), the net effect could nonetheless
be progressive.
</p><!-- l. 610 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='implications-for-health-litigation-institutions'><span class='titlemark'>10.3   </span> <a id='x1-5500010.3'></a>Implications for Health Litigation Institutions</h4>
<!-- l. 612 --><p class='noindent'>Our estimates translate to specific policy counterfactuals: tightening preliminary
injunction standards, mandating NAT-Jus technical review before granting,
raising evidentiary thresholds for off-formulary drugs (as in Tema 106), or
requiring administrative exhaustion before litigation. If marginal returns to
judicial spending are negative, welfare arguments favor raising the evidentiary
threshold further, because the marginal case is welfare-reducing. If marginal
returns are positive, reforms should prioritize targeting (directing judicial
resources toward high-return cases) rather than restriction.
</p><!-- l. 614 --><p class='indent'>   More broadly, the comparison of judicial and administrative returns
informs whether demand should be channeled away from courts. If judicial
allocation is less efficient, administrative resolution mechanisms—which
several municipalities have already developed—may improve population
                                                                          

                                                                          
health.<span class='footnote-mark'><a href='main17.html#fn16x0'><sup class='textsuperscript'>16</sup></a></span><a id='x1-55001f16'></a> 
If the two are comparable, the equity dimension becomes decisive.
</p><!-- l. 616 --><p class='indent'>   Frontier therapies amplify the information problem. When courts override
both the regulatory agency and the health technology assessment body under high
clinical uncertainty, the wedge between judicial and administrative allocation is
likely largest. A recent gene therapy case illustrates the pattern: despite
suspended regulatory registration and a negative HTA assessment, over 200 active
lawsuits sought to compel SUS to provide the treatment at a potential cost of R$3
billion.<span class='footnote-mark'><a href='main18.html#fn17x0'><sup class='textsuperscript'>17</sup></a></span><a id='x1-55002f17'></a> 
The efficiency costs of judicial allocation may be most acute where the
information disadvantage of courts relative to specialized assessment bodies is
greatest.
</p>
                                                                          

                                                                          
   <h4 class='subsectionHead' id='lessons-beyond-brazil'><span class='titlemark'>10.4   </span> <a id='x1-5600010.4'></a>Lessons Beyond Brazil</h4>
<!-- l. 620 --><p class='noindent'>Health judicialization is growing in middle-income countries with constitutionalized
social rights, including Colombia, Costa Rica, South Africa, and India. Brazil
offers the largest and most mature case, but the underlying question—whether
judicial intervention improves or worsens the allocation of scarce public
resources—generalizes wherever adjudicators impose case-driven, ex post spending
mandates on fixed budgets.
</p><!-- l. 623 --><p class='noindent'>
</p>
   <h3 class='sectionHead' id='conclusion'><span class='titlemark'>11   </span> <a id='x1-5700011'></a>Conclusion</h3>
<!-- l. 626 --><p class='noindent'>This paper estimates the causal effect of court-mandated health spending on
budget composition, population health, and distributional incidence in Brazil.
Exploiting random assignment of judges to health lawsuits, we use judge
stringency as an instrument for court-mandated spending to identify its effects at
the municipality level.
</p><!-- l. 634 --><p class='indent'>   The combination of direct spending measurement in budget execution
records and a judge-IV design allows us to trace the full chain from judicial
mandates through budget composition to population health and distributional
incidence—providing direct evidence on how the mode of allocation shapes the
returns to public spending.
</p><!-- l. 636 --><p class='indent'>   The analysis has limitations. Our estimates identify a local average treatment
effect for marginal cases affected by judge stringency—cases that may be
                                                                          

                                                                          
disproportionately supply-driven and thus yield lower health returns than
infra-marginal cases. The focus on São Paulo, while offering a large and
well-documented setting, limits external validity to states with different health
system capacities and litigation patterns. And our judicial spending measure relies
on text-based identification that may understate true judicial spending if
municipalities inconsistently tag expenditures.
</p><!-- l. 638 --><p class='indent'>   These limitations notwithstanding, our results speak to a question that
extends well beyond Brazil: whether the institution that allocates public
spending—courts versus administrative agencies—matters for the outcomes it
produces. As courts around the world increasingly adjudicate claims to social
services, understanding the efficiency and distributional consequences of this
judicial role becomes central to institutional design.
</p><!-- l. 641 --><p class='noindent'>
</p>
   <h4 class='likesubsectionHead' id='data-availability-statement'><a id='x1-5800011'></a>Data Availability Statement</h4>
<!-- l. 643 --><p class='noindent'>The litigation data are constructed from publicly available records: DataJud
(<a id='x1-58001'></a>Conselho Nacional de Justiça, <a href='#cite.0@datajud'>2020</a>), the TJSP electronic gazette, and the
Consulta de Julgados portal (<a id='x1-58002'></a>Tribunal de Justiça do Estado de São Paulo,
<a href='#cite.0@tjsp_esaj'>2024</a>). Municipal budget execution data are published by TCE-SP through its
transparency portal (<a id='x1-58003'></a>Tribunal de Contas do Estado de São Paulo, <a href='#cite.0@tcesp_audesp'>2024</a>). Health
outcomes are from DATASUS registries (SIH, SIM, SINASC), which are
publicly available. Individual-level linkage to RAIS and CadÚnico requires
restricted-access authorization from the Brazilian Ministry of Labor and
                                                                          

                                                                          
the Ministry of Social Development, respectively. Replication code and
instructions for accessing the public data sources will be made available upon
publication.
</p><!-- l. 646 --><p class='noindent'>
</p>
   <h3 class='sectionHead' id='references'><a id='x1-5900011'></a>References</h3>
<!-- l. 646 --><p class='noindent'>
       </p><dl class='thebibliography'><dt class='thebibliography' id='X0-alfradique2009csp'>
</dt><dd class='thebibliography' id='bib-1'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@alfradique2009csp'></a>Alfradique, M. E., Bonolo, P. d. F., Dourado, I., Lima-Costa, M. F.,
       Macinko, J., Mendonça, C. S., Oliveira, V. B., Sampaio, L. F. R.,
       De Simoni, C., &amp; Turci, M. A. (2009). Internações por condições
       sensíveis à atenção primária: A construção da lista brasileira
       como  ferramenta  para  medir  o  desempenho  do  sistema  de  saúde
       (Projeto  ICSAP  –  Brasil).  <span class='ecti-1200'>Cadernos  de  Saúde  Pública</span>,  <span class='ecti-1200'>25</span>(6),
       1337–1349. <a href='https://doi.org/10.1590/S0102-311X2009000600016'>https://doi.org/10.1590/S0102-311X2009000600016</a>
       </p></dd><dt class='thebibliography' id='X0-andialamprea2019bmjgh'>
</dt><dd class='thebibliography' id='bib-2'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@andialamprea2019bmjgh'></a>Andia, T. S., &amp; Lamprea, E. (2019). Is the judicialization of health
       care  bad  for  equity?  a  scoping  review.  <span class='ecti-1200'>BMJ  Global  Health</span>,  <span class='ecti-1200'>4</span>(5),
       e002004. <a href='https://doi.org/10.1136/bmjgh-2019-002004'>https://doi.org/10.1136/bmjgh-2019-002004</a>
                                                                          

                                                                          
       </p></dd><dt class='thebibliography' id='X0-anstreicher2022nber'>
</dt><dd class='thebibliography' id='bib-3'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@anstreicher2022nber'></a>Anstreicher, G., Fletcher, J., &amp; Thompson, O. (2022). <span class='ecti-1200'>The long run
       </span><span class='ecti-1200'>impacts of court-ordered desegregation </span>(Working Paper No. 29926).
       National Bureau of Economic Research. <a href='https://doi.org/10.3386/w29926'>https://doi.org/10.3386/
       w29926</a>
       </p></dd><dt class='thebibliography' id='X0-aquino2009ajph'>
</dt><dd class='thebibliography' id='bib-4'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@aquino2009ajph'></a>Aquino,  R.,  de  Oliveira,  N. F.,  &amp;  Barreto,  M. L.  (2009).  Impact
       of  the  Family  Health  Program  on  infant  mortality  in  Brazilian
       municipalities.  <span class='ecti-1200'>American Journal of Public Health</span>,  <span class='ecti-1200'>99</span>(1),  87–93.  <a href='https://doi.org/10.2105/AJPH.2007.127480'>https://doi.org/10.2105/AJPH.2007.127480</a>
       </p></dd><dt class='thebibliography' id='X0-arrietagomez2018hhr'>
</dt><dd class='thebibliography' id='bib-5'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@arrietagomez2018hhr'></a>Arrieta-Gómez,  A. I.  (2018).  Realizing  the  fundamental  right  to
       health through litigation: The Colombian case. <span class='ecti-1200'>Health and Human
       </span><span class='ecti-1200'>Rights</span>, <span class='ecti-1200'>20</span>(1), 133–145.
       </p></dd><dt class='thebibliography' id='X0-arrow1963aer'>
</dt><dd class='thebibliography' id='bib-6'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@arrow1963aer'></a>Arrow,  K. J.  (1963).  Uncertainty  and  the  welfare  economics  of
       medical care. <span class='ecti-1200'>American Economic Review</span>, <span class='ecti-1200'>53</span>(5), 941–973.
       </p></dd><dt class='thebibliography' id='X0-bhuller2020'>
</dt><dd class='thebibliography' id='bib-7'>
                                                                          

                                                                          
       <!-- l. 646 --><p class='noindent'><a id='cite.0@bhuller2020'></a>Bhuller,  M.,  Dahl,  G. B.,  Løken,  K. V.,  &amp;  Mogstad,  M.  (2020).
       Incarceration,  recidivism,  and  employment.  <span class='ecti-1200'>Journal  of  Political
       </span><span class='ecti-1200'>Economy</span>, <span class='ecti-1200'>128</span>(4), 1269–1324. <a href='https://doi.org/10.1086/705330'>https://doi.org/10.1086/705330</a>
       </p></dd><dt class='thebibliography' id='X0-biehl2012hhr'>
</dt><dd class='thebibliography' id='bib-8'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@biehl2012hhr'></a>Biehl, J., Amon, J. J., Socal, M. P., &amp; Petryna, A. (2012). Between
       the court and the clinic: Lawsuits for medicines and the right to health
       in Brazil. <span class='ecti-1200'>Health and Human Rights</span>, <span class='ecti-1200'>14</span>(1), E36–E52.
       </p></dd><dt class='thebibliography' id='X0-biehl2016hhr'>
</dt><dd class='thebibliography' id='bib-9'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@biehl2016hhr'></a>Biehl,  J.,  Petryna,  A.,  Amon,  J. J.,  &amp;  Socal,  M. P.  (2016).  The
       judicialization  of  health  and  the  quest  for  state  accountability:
       Evidence  from  1,262  lawsuits  for  access  to  medicines  in  Southern
       Brazil. <span class='ecti-1200'>Health and Human Rights</span>, <span class='ecti-1200'>18</span>(2), 209–220.
       </p></dd><dt class='thebibliography' id='X0-biehl2009lancet'>
</dt><dd class='thebibliography' id='bib-10'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@biehl2009lancet'></a>Biehl,  J.,  Petryna,  A.,  Gertner,  A.,  Amon,  J. J.,  &amp;  Picon,  P. D.
       (2009). Judicialisation of the right to health in Brazil. <span class='ecti-1200'>The Lancet</span>,
       <span class='ecti-1200'>373</span>(9682), 2182–2184. <a href='https://doi.org/10.1016/S0140-6736(09)61172-7'>https://doi.org/10.1016/S0140-6736(09)
       61172-7</a>
       </p></dd><dt class='thebibliography' id='X0-biehl2015csp'>
</dt><dd class='thebibliography' id='bib-11'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@biehl2015csp'></a>Biehl, J., Socal, M. P., &amp; Amon, J. J. (2015). The judicialization of
       health and the quest for state accountability: Evidence from 1,262
       lawsuits  for  access  to  medicines  in  Southern  Brazil.  <span class='ecti-1200'>Cadernos  de
                                                                          

                                                                          
       </span><span class='ecti-1200'>Saúde Pública</span>, <span class='ecti-1200'>31</span>(3), 451–462. <a href='https://doi.org/10.1590/0102-311X00048514'>https://doi.org/10.1590/0102-
       311X00048514</a>
       </p></dd><dt class='thebibliography' id='X0-bokhari2007he'>
</dt><dd class='thebibliography' id='bib-12'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@bokhari2007he'></a>Bokhari, F. A. S., Gai, Y., &amp; Gottret, P. (2007). Government health
       expenditures and health outcomes. <span class='ecti-1200'>Health Economics</span>, <span class='ecti-1200'>16</span>(3), 257–273.
       <a href='https://doi.org/10.1002/hec.1157'>https://doi.org/10.1002/hec.1157</a>
       </p></dd><dt class='thebibliography' id='X0-borgschulte2020jhe'>
</dt><dd class='thebibliography' id='bib-13'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@borgschulte2020jhe'></a>Borgschulte,  M.,  &amp;  Vogler,  J.  (2020).  Did  the  ACA  Medicaid
       expansion  save  lives?  <span class='ecti-1200'>Journal  of  Health  Economics</span>,  <span class='ecti-1200'>72</span>,  102333.  <a href='https://doi.org/10.1016/j.jhealeco.2020.102333'>https://doi.org/10.1016/j.jhealeco.2020.102333</a>
       </p></dd><dt class='thebibliography' id='X0-borusyak2022restat'>
</dt><dd class='thebibliography' id='bib-14'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@borusyak2022restat'></a>Borusyak,  K.,  Hull,  P.,  &amp;  Jaravel,  X.  (2022).  Quasi-experimental
       shift-share  research  designs.  <span class='ecti-1200'>Review  of  Economic  Studies</span>,  <span class='ecti-1200'>89</span>(1),
       181–213.
       </p></dd><dt class='thebibliography' id='X0-theconversation2024'>
</dt><dd class='thebibliography' id='bib-15'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@theconversation2024'></a>Brito, J. C. Z. d. (2024). Judicialização consumiu de 30% a 100%
       da verba da saúde em mais de 250 cidades brasileiras. <span class='ecti-1200'>The Conversation</span>.
       <a class='url' href='https://theconversation.com/judicializacao-consumiu-de-30-a-100-da-verba-da-saude-em-mais-de-250-cidades-brasileiras-230387'>https://theconversation.com/judicializacao-consumiu-de-30-a-100-da-verba-da-saude-em-mais-de-250-cidades-brasileiras-230387</a>.
       </p></dd><dt class='thebibliography' id='X0-buchanan1963jpe'>
</dt><dd class='thebibliography' id='bib-16'>
                                                                          

                                                                          
       <!-- l. 646 --><p class='noindent'><a id='cite.0@buchanan1963jpe'></a>Buchanan, J. M. (1963). The economics of earmarked taxes. <span class='ecti-1200'>Journal
       </span><span class='ecti-1200'>of Political Economy</span>, <span class='ecti-1200'>71</span>(5), 457–469. <a href='https://doi.org/10.1086/258794'>https://doi.org/10.1086/
       258794</a>
       </p></dd><dt class='thebibliography' id='X0-cambricoli2016estadao'>
</dt><dd class='thebibliography' id='bib-17'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@cambricoli2016estadao'></a>Cambricoli, F. (2016). Gasto do governo com remédio sem aval da
       Anvisa cresce 220 vezes em 5 anos. <span class='ecti-1200'>O Estado de S. Paulo</span>.   <a class='url' href='https://noticias.uol.com.br/saude/ultimas-noticias/estado/2016/10/17/gasto-do-governo-com-remedio-sem-aval-da-anvisa-cresce-220-vezes-em-5-anos.htm'>https://noticias.uol.com.br/saude/ultimas-noticias/estado/2016/10/17/gasto-do-governo-com-remedio-sem-aval-da-anvisa-cresce-220-vezes-em-5-anos.htm</a>.
       </p></dd><dt class='thebibliography' id='X0-castro2019lancet'>
</dt><dd class='thebibliography' id='bib-18'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@castro2019lancet'></a>Castro,  M. C.,  Massuda,  A.,  Almeida,  G.,  Menezes-Filho,  N. A.,
       Andrade, M. V., de Souza Noronha, K. V. M., Rocha, R., Macinko,
       J., Hone, T., Tasca, R., Giovanella, L., Malik, A. M., Werneck, H.,
       Fachini, L. A., &amp; Atun, R. (2019). Brazil’s unified health system: The
       first 30 years and prospects for the future. <span class='ecti-1200'>The Lancet</span>, <span class='ecti-1200'>394</span>(10195),
       345–356. <a href='https://doi.org/10.1016/S0140-6736(19)31243-7'>https://doi.org/10.1016/S0140-6736(19)31243-7</a>
       </p></dd><dt class='thebibliography' id='X0-chieffi2009csp'>
</dt><dd class='thebibliography' id='bib-19'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@chieffi2009csp'></a>Chieffi, A. L., &amp; Barata, R. B. (2009). Judicialização da política
       pública  de  assistência  farmacêutica  e  equidade.  <span class='ecti-1200'>Cadernos  de
       </span><span class='ecti-1200'>Saúde Pública</span>, <span class='ecti-1200'>25</span>(8), 1839–1849. <a href='https://doi.org/10.1590/S0102-311X2009000800020'>https://doi.org/10.1590/S0102-
       311X2009000800020</a>
       </p></dd><dt class='thebibliography' id='X0-chieffibarata2010rsp'>
</dt><dd class='thebibliography' id='bib-20'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@chieffibarata2010rsp'></a>Chieffi,   A. L.,   &amp;   Barata,   R. B.   (2010).   Ações   judiciais:
       Estratégia da indústria farmacêutica para introdução de novos
                                                                          

                                                                          
       medicamentos. <span class='ecti-1200'>Revista de Saúde Pública</span>, <span class='ecti-1200'>44</span>(3), 421–429. <a href='https://doi.org/10.1590/S0034-89102010000300005'>https:
       //doi.org/10.1590/S0034-89102010000300005</a>
       </p></dd><dt class='thebibliography' id='X0-chyn2025jel'>
</dt><dd class='thebibliography' id='bib-21'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@chyn2025jel'></a>Chyn,  E.,  Frandsen,  B.,  &amp;  Leslie,  E.  (2025).  Examiner  and  judge
       designs in economics: A practitioner’s guide. <span class='ecti-1200'>Journal of Economic
       </span><span class='ecti-1200'>Literature</span>, <span class='ecti-1200'>63</span>(2), 401–439.
       </p></dd><dt class='thebibliography' id='X0-cnjinsper2019'>
</dt><dd class='thebibliography' id='bib-22'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@cnjinsper2019'></a>CNJ/INSPER. (2019). <span class='ecti-1200'>Judicialização da saúde no Brasil: Perfil
       </span><span class='ecti-1200'>das demandas, causas e propostas de solução </span>(tech. rep.). Conselho
       Nacional de Justiça and Instituto de Ensino e Pesquisa.   <a class='url' href='https://www.cnj.jus.br/wp-content/uploads/conteudo/arquivo/2019/03/f74c66d46cfea933bf22005ca50ec915.pdf'>https://www.cnj.jus.br/wp-content/uploads/conteudo/arquivo/2019/03/f74c66d46cfea933bf22005ca50ec915.pdf</a>
       </p></dd><dt class='thebibliography' id='X0-cnm2022'>
</dt><dd class='thebibliography' id='bib-23'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@cnm2022'></a>Confederação  Nacional  de  Municípios.  (2022).  <span class='ecti-1200'>Pesquisa  sobre
       </span><span class='ecti-1200'>desabastecimento de medicamentos nos municípios</span>. CNM.
       </p></dd><dt class='thebibliography' id='X0-cfm2024'>
</dt><dd class='thebibliography' id='bib-24'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@cfm2024'></a>Conselho  Federal  de  Medicina.  (2024).  <span class='ecti-1200'>Crise  no  SUS:  Pacientes
       </span><span class='ecti-1200'>aguardam mais de 10 anos na fila de espera</span>. CFM.
       </p></dd><dt class='thebibliography' id='X0-datajud'>
</dt><dd class='thebibliography' id='bib-25'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@datajud'></a>Conselho Nacional de Justiça. (2020). DataJud: Base nacional de
       dados do poder judiciário [Resolução CNJ 331/2020].
                                                                          

                                                                          
       </p></dd><dt class='thebibliography' id='X0-cnjpnud2025'>
</dt><dd class='thebibliography' id='bib-26'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@cnjpnud2025'></a>Conselho Nacional de Justiça &amp; Programa das Nações Unidas
       para o Desenvolvimento. (2025). <span class='ecti-1200'>Diagnóstico da judicialização da
       </span><span class='ecti-1200'>saúde pública e suplementar</span>. CNJ/PNUD.
       </p></dd><dt class='thebibliography' id='X0-cgu2021conitec'>
</dt><dd class='thebibliography' id='bib-27'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@cgu2021conitec'></a>Controladoria-Geral  da  União.  (2021).  <span class='ecti-1200'>Relatório  de  avaliação:
       </span><span class='ecti-1200'>Processo de incorporação de tecnologias em saúde no âmbito do
       </span><span class='ecti-1200'>SUS </span>(Audit Report). CGU.
       </p></dd><dt class='thebibliography' id='X0-correia2025natjus'>
</dt><dd class='thebibliography' id='bib-28'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@correia2025natjus'></a>Correia, L. R., et al. (2025). Impact evaluation of technical notes
       issued by NATJUS on judicial decisions in health [PMC12176339].
       <span class='ecti-1200'>PubMed Central</span>.
       </p></dd><dt class='thebibliography' id='X0-diniz2014csc'>
</dt><dd class='thebibliography' id='bib-29'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@diniz2014csc'></a>Diniz,   D.,   Machado,   T. R. d. C.,   &amp;   Penalva,   J.   (2014).   A
       judicialização da saúde no Distrito Federal, Brasil. <span class='ecti-1200'>Ciência &amp;
       </span><span class='ecti-1200'>Saúde Coletiva</span>, <span class='ecti-1200'>19</span>(2), 591–598. <a href='https://doi.org/10.1590/1413-81232014192.23072012'>https://doi.org/10.1590/1413-
       81232014192.23072012</a>
       </p></dd><dt class='thebibliography' id='X0-dobbie2018'>
</dt><dd class='thebibliography' id='bib-30'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@dobbie2018'></a>Dobbie, W., Goldin, J., &amp; Yang, C. S. (2018). The effects of pretrial
       detention  on  conviction,  future  crime,  and  employment:  Evidence
                                                                          

                                                                          
       from randomly assigned judges. <span class='ecti-1200'>American Economic Review</span>, <span class='ecti-1200'>108</span>(2),
       201–240. <a href='https://doi.org/10.1257/aer.20161503'>https://doi.org/10.1257/aer.20161503</a>
       </p></dd><dt class='thebibliography' id='X0-ferraz2009hhr'>
</dt><dd class='thebibliography' id='bib-31'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@ferraz2009hhr'></a>Ferraz, O. L. M. (2009). The right to health in the courts of Brazil:
       Worsening health inequities? <span class='ecti-1200'>Health and Human Rights</span>, <span class='ecti-1200'>11</span>(2), 33–45.
       </p></dd><dt class='thebibliography' id='X0-filmer1999wber'>
</dt><dd class='thebibliography' id='bib-32'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@filmer1999wber'></a>Filmer, D., &amp; Pritchett, L. (1999). The impact of public spending
       on health: Does money matter? <span class='ecti-1200'>Social Science &amp; Medicine</span>, <span class='ecti-1200'>49</span>(10),
       1309–1323. <a href='https://doi.org/10.1016/S0277-9536(99)00150-1'>https://doi.org/10.1016/S0277-9536(99)00150-1</a>
       </p></dd><dt class='thebibliography' id='X0-finkelstein2019qje'>
</dt><dd class='thebibliography' id='bib-33'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@finkelstein2019qje'></a>Finkelstein, A., Hendren, N., &amp; Luttmer, E. F. P. (2019). The value
       of Medicaid: Interpreting results from the Oregon Health Insurance
       Experiment.  <span class='ecti-1200'>Journal  of  Political  Economy</span>,  <span class='ecti-1200'>127</span>(6),  2836–2874.  <a href='https://doi.org/10.1086/702238'>https://doi.org/10.1086/702238</a>
       </p></dd><dt class='thebibliography' id='X0-folha2020eculizumab'>
</dt><dd class='thebibliography' id='bib-34'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@folha2020eculizumab'></a>Folha de S.Paulo. (2020). Um único remédio custou ao SUS R$2,44
       bilhões em 11 anos, revela estudo. <span class='ecti-1200'>Folha de S.Paulo</span>.   <a class='url' href='https://www1.folha.uol.com.br/cotidiano/2020/03/um-unico-remedio-custou-ao-sus-r-244-bilhoes-em-11-anos-revela-estudo.shtml'>https://www1.folha.uol.com.br/cotidiano/2020/03/um-unico-remedio-custou-ao-sus-r-244-bilhoes-em-11-anos-revela-estudo.shtml</a>.
       </p></dd><dt class='thebibliography' id='X0-folha2025incorporation'>
</dt><dd class='thebibliography' id='bib-35'>
                                                                          

                                                                          
       <!-- l. 646 --><p class='noindent'><a id='cite.0@folha2025incorporation'></a>Folha de S.Paulo. (2025a). SUS não entrega ao menos 76 medicamentos
       e procedimentos incorporados à rede pública desde 2018. <span class='ecti-1200'>Folha de
       </span><span class='ecti-1200'>S.Paulo</span>.   <a class='url' href='https://www1.folha.uol.com.br/equilibrioesaude/2025/01/sus-nao-entrega-ao-menos-76-medicamentos-e-procedimentos-incorporados-a-rede-publica-desde-2018.shtml'>https://www1.folha.uol.com.br/equilibrioesaude/2025/01/sus-nao-entrega-ao-menos-76-medicamentos-e-procedimentos-incorporados-a-rede-publica-desde-2018.shtml</a>.
       </p></dd><dt class='thebibliography' id='X0-folha2025elevidys'>
</dt><dd class='thebibliography' id='bib-36'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@folha2025elevidys'></a>Folha de S.Paulo. (2025b). Ministério da saúde paga R$2,7 bilhões
       com medicamentos judicializados e teme explosão de custos. <span class='ecti-1200'>Folha de
       </span><span class='ecti-1200'>S.Paulo</span>.   <a class='url' href='https://www1.folha.uol.com.br/equilibrioesaude/2025/08/ministerio-da-saude-paga-r-2-7-bilhoes-com-medicamentos-judicializados-e-teme-explosao-de-custos.shtml'>https://www1.folha.uol.com.br/equilibrioesaude/2025/08/ministerio-da-saude-paga-r-2-7-bilhoes-com-medicamentos-judicializados-e-teme-explosao-de-custos.shtml</a>.
       </p></dd><dt class='thebibliography' id='X0-frandsen2023aer'>
</dt><dd class='thebibliography' id='bib-37'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@frandsen2023aer'></a>Frandsen, B. R., Lefgren, L. J., &amp; Leslie, E. C. (2023). Judging judge
       fixed effects. <span class='ecti-1200'>American Economic Review</span>, <span class='ecti-1200'>113</span>(1), 253–277. <a href='https://doi.org/10.1257/aer.20201860'>https:
       //doi.org/10.1257/aer.20201860</a>
       </p></dd><dt class='thebibliography' id='X0-funcia2018sd'>
</dt><dd class='thebibliography' id='bib-38'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@funcia2018sd'></a>Funcia,  F.,  &amp;  Ocke-Reis,  C. O.  (2018).  O  subfinanciamento  e  o
       desfinanciamento do SUS. <span class='ecti-1200'>Saúde em Debate</span>, <span class='ecti-1200'>42</span>(spe1).
       </p></dd><dt class='thebibliography' id='X0-galanter1974lsr'>
</dt><dd class='thebibliography' id='bib-39'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@galanter1974lsr'></a>Galanter, M. (1974). Why the “haves” come out ahead: Speculations
       on the limits of legal change. <span class='ecti-1200'>Law &amp; Society Review</span>, <span class='ecti-1200'>9</span>(1), 95–160. <a href='https://doi.org/10.2307/3053023'>https://doi.org/10.2307/3053023</a>
       </p></dd><dt class='thebibliography' id='X0-gauribrinks2008'>
</dt><dd class='thebibliography' id='bib-40'>
                                                                          

                                                                          
       <!-- l. 646 --><p class='noindent'><a id='cite.0@gauribrinks2008'></a>Gauri, V., &amp; Brinks, D. M. (2008). <span class='ecti-1200'>Courting social justice: Judicial
       </span><span class='ecti-1200'>enforcement of social and economic rights in the developing world</span>.
       Cambridge University Press.
       </p></dd><dt class='thebibliography' id='X0-genicolom2024wp'>
</dt><dd class='thebibliography' id='bib-41'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@genicolom2024wp'></a>Genicolo-Martins, D., &amp; Furquim de Azevedo, P. (2024). <span class='ecti-1200'>Bitter pills
       </span><span class='ecti-1200'>to swallow: The enforcement costs of health litigation </span>[Working Paper,
       Insper].   <a class='url' href='https://darciogm.github.io/research/202402_Paper_1_Health_Litigation.pdf'>https://darciogm.github.io/research/202402_Paper_1_Health_Litigation.pdf</a>
       </p></dd><dt class='thebibliography' id='X0-gloppen2006jhr'>
</dt><dd class='thebibliography' id='bib-42'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@gloppen2006jhr'></a>Gloppen, S. (2006). Courts and social transformation: An analytical
       framework. <span class='ecti-1200'>Journal of Human Rights</span>, <span class='ecti-1200'>5</span>(1).
       </p></dd><dt class='thebibliography' id='X0-goldsmithpinkham2025'>
</dt><dd class='thebibliography' id='bib-43'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@goldsmithpinkham2025'></a>Goldsmith-Pinkham, P., Hull, P., &amp; Kolesár, M. (2025). <span class='ecti-1200'>Leniency
       </span><span class='ecti-1200'>designs: An operator’s manual </span>(Working Paper No. 34473). National
       Bureau of Economic Research. <a href='https://doi.org/10.3386/w34473'>https://doi.org/10.3386/w34473</a>
       </p></dd><dt class='thebibliography' id='X0-grossman1972jpe'>
</dt><dd class='thebibliography' id='bib-44'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@grossman1972jpe'></a>Grossman,  M.  (1972).  On  the  concept  of  health  capital  and  the
       demand for health. <span class='ecti-1200'>Journal of Political Economy</span>, <span class='ecti-1200'>80</span>(2), 223–255. <a href='https://doi.org/10.1086/259880'>https://doi.org/10.1086/259880</a>
       </p></dd><dt class='thebibliography' id='X0-hanushek2023pfr'>
</dt><dd class='thebibliography' id='bib-45'>
                                                                          

                                                                          
       <!-- l. 646 --><p class='noindent'><a id='cite.0@hanushek2023pfr'></a>Hanushek,  E. A.,  Joyce,  T.,  &amp;  Wirtz,  P.  (2023).  Incidence  and
       outcomes of school finance litigation. <span class='ecti-1200'>Public Finance Review</span>, <span class='ecti-1200'>51</span>(6).
       </p></dd><dt class='thebibliography' id='X0-higgins2016roiw'>
</dt><dd class='thebibliography' id='bib-46'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@higgins2016roiw'></a>Higgins,  S.,  Lustig,  N.,  Ruble,  W.,  &amp;  Smeeding,  T. M.  (2016).
       Comparing the incidence of taxes and social spending in Brazil and
       the United States. <span class='ecti-1200'>Review of Income and Wealth</span>, <span class='ecti-1200'>62</span>(S1), S22–S46. <a href='https://doi.org/10.1111/roiw.12201'>https://doi.org/10.1111/roiw.12201</a>
       </p></dd><dt class='thebibliography' id='X0-hinesthaler1995jep'>
</dt><dd class='thebibliography' id='bib-47'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@hinesthaler1995jep'></a>Hines, J. R., &amp; Thaler, R. H. (1995). The flypaper effect. <span class='ecti-1200'>Journal of
       </span><span class='ecti-1200'>Economic Perspectives</span>, <span class='ecti-1200'>9</span>(4), 217–226. <a href='https://doi.org/10.1257/jep.9.4.217'>https://doi.org/10.1257/
       jep.9.4.217</a>
       </p></dd><dt class='thebibliography' id='X0-hone2023lancetamericas'>
</dt><dd class='thebibliography' id='bib-48'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@hone2023lancetamericas'></a>Hone,  T.,  et  al.  (2023).  Associations  between  primary  healthcare
       and infant health outcomes in Brazil. <span class='ecti-1200'>The Lancet Regional Health –
       </span><span class='ecti-1200'>Americas</span>. <a href='https://doi.org/10.1016/j.lana.2023.100493'>https://doi.org/10.1016/j.lana.2023.100493</a>
       </p></dd><dt class='thebibliography' id='X0-hone2017plosmed'>
</dt><dd class='thebibliography' id='bib-49'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@hone2017plosmed'></a>Hone, T., Rasella, D., Barreto, M. L., Atun, R., Majeed, A., &amp; Millett,
       C. (2017). Association between expansion of primary healthcare and
       racial inequalities in mortality amenable to primary care in Brazil.
       <span class='ecti-1200'>PLOS Medicine</span>, <span class='ecti-1200'>14</span>(5), e1002306. <a href='https://doi.org/10.1371/journal.pmed.1002306'>https://doi.org/10.1371/journal.
       pmed.1002306</a>
                                                                          

                                                                          
       </p></dd><dt class='thebibliography' id='X0-imbens1994'>
</dt><dd class='thebibliography' id='bib-50'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@imbens1994'></a>Imbens, G. W., &amp; Angrist, J. D. (1994). Identification and estimation
       of  local  average  treatment  effects.  <span class='ecti-1200'>Econometrica</span>,  <span class='ecti-1200'>62</span>(2),  467–475.  <a href='https://doi.org/10.2307/2951620'>https://doi.org/10.2307/2951620</a>
       </p></dd><dt class='thebibliography' id='X0-ipea2025'>
</dt><dd class='thebibliography' id='bib-51'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@ipea2025'></a>Instituto  de  Pesquisa  Econômica  Aplicada.  (2025).  <span class='ecti-1200'>Assistência
       </span><span class='ecti-1200'>farmacêutica  no  SUS:  Panorama  2019–2023  </span>(Research  Report).
       IPEA.
       </p></dd><dt class='thebibliography' id='X0-ipea_anadep2013'>
</dt><dd class='thebibliography' id='bib-52'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@ipea_anadep2013'></a>Instituto de Pesquisa Econômica Aplicada &amp; Associação Nacional
       dos Defensores Públicos. (2013). <span class='ecti-1200'>Mapa da Defensoria Pública no
       </span><span class='ecti-1200'>Brasil</span>. IPEA.
       </p></dd><dt class='thebibliography' id='X0-jackson2016qje'>
</dt><dd class='thebibliography' id='bib-53'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@jackson2016qje'></a>Jackson, C. K., Johnson, R. C., &amp; Persico, C. (2016). The effects
       of school spending on educational and economic outcomes: Evidence
       from school finance reforms. <span class='ecti-1200'>Quarterly Journal of Economics</span>, <span class='ecti-1200'>131</span>(1),
       157–218. <a href='https://doi.org/10.1093/qje/qjv036'>https://doi.org/10.1093/qje/qjv036</a>
       </p></dd><dt class='thebibliography' id='X0-kling2006'>
</dt><dd class='thebibliography' id='bib-54'>
                                                                          

                                                                          
       <!-- l. 646 --><p class='noindent'><a id='cite.0@kling2006'></a>Kling, J. R. (2006). Incarceration length, employment, and earnings.
       <span class='ecti-1200'>American Economic Review</span>, <span class='ecti-1200'>96</span>(3), 863–876. <a href='https://doi.org/10.1257/aer.96.3.863'>https://doi.org/10.
       1257/aer.96.3.863</a>
       </p></dd><dt class='thebibliography' id='X0-lafortune2018nber'>
</dt><dd class='thebibliography' id='bib-55'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@lafortune2018nber'></a>Lafortune, J., Rothstein, J., &amp; Schanzenbach, D. W. (2018). <span class='ecti-1200'>School
       </span><span class='ecti-1200'>finance reform and the distribution of student achievement </span>(Working
       Paper No. 22011). National Bureau of Economic Research. <a href='https://doi.org/10.3386/w22011'>https:
       //doi.org/10.3386/w22011</a>
       </p></dd><dt class='thebibliography' id='X0-litschig2012aejep'>
</dt><dd class='thebibliography' id='bib-56'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@litschig2012aejep'></a>Litschig,         S.,         &amp;         Morrison,         K. M.         (2012).
       The impact of intergovernmental transfers on education outcomes and
       poverty reduction. <span class='ecti-1200'>American Economic Journal: Applied Economics</span>,
       <span class='ecti-1200'>4</span>(3), 136–163. <a href='https://doi.org/10.1257/app.4.3.136'>https://doi.org/10.1257/app.4.3.136</a>
       </p></dd><dt class='thebibliography' id='X0-loaiza2018hhr'>
</dt><dd class='thebibliography' id='bib-57'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@loaiza2018hhr'></a>Loaiza, O. R., et al. (2018). Revisiting health rights litigation and
       access to medications in Costa Rica: A follow-up study. <span class='ecti-1200'>Health and
       </span><span class='ecti-1200'>Human Rights</span>, <span class='ecti-1200'>20</span>(1), 79–91.
       </p></dd><dt class='thebibliography' id='X0-lustig2013wd'>
</dt><dd class='thebibliography' id='bib-58'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@lustig2013wd'></a>Lustig, N., Lopez-Calva, L. F., &amp; Ortiz-Juarez, E. (2013). Declining
       inequality in Latin America in the 2000s: The cases of Argentina,
                                                                          

                                                                          
       Brazil, and Mexico. <span class='ecti-1200'>World Development</span>, <span class='ecti-1200'>44</span>, 129–141. <a href='https://doi.org/10.1016/j.worlddev.2012.09.013'>https://doi.
       org/10.1016/j.worlddev.2012.09.013</a>
       </p></dd><dt class='thebibliography' id='X0-machado2011rsp'>
</dt><dd class='thebibliography' id='bib-59'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@machado2011rsp'></a>Machado,  M. A. d. Á.,  Acurcio,  F. d. A.,  Brandão,  C. M. R.,
       Faleiros,  D. R.,  Guerra  Júnior,  A. A.,  Cherchiglia,  M. L.,  &amp;
       Andrade, E. I. G. (2011). Judicialization of access to medicines in
       the state of Minas Gerais, Southeastern Brazil. <span class='ecti-1200'>Revista de Saúde
       </span><span class='ecti-1200'>Pública</span>,  <span class='ecti-1200'>45</span>(3),  590–598.  <a href='https://doi.org/10.1590/S0034-89102011005000015'>https : / / doi . org / 10 . 1590 / S0034 -
       89102011005000015</a>
       </p></dd><dt class='thebibliography' id='X0-macinko2006jech'>
</dt><dd class='thebibliography' id='bib-60'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@macinko2006jech'></a>Macinko,  J.,  Guanais,  F. C.,  de  Fatima,  M.,  &amp;  de  Souza,  M.
       (2006). Evaluation of the impact of the Family Health Program on
       infant mortality in Brazil, 1990–2002. <span class='ecti-1200'>Journal of Epidemiology and
       </span><span class='ecti-1200'>Community Health</span>, <span class='ecti-1200'>60</span>(1), 13–19. <a href='https://doi.org/10.1136/jech.2005.038323'>https://doi.org/10.1136/jech.
       2005.038323</a>
       </p></dd><dt class='thebibliography' id='X0-maestas2013'>
</dt><dd class='thebibliography' id='bib-61'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@maestas2013'></a>Maestas,  N.,  Mullen,  K. J.,  &amp;  Strand,  A.  (2013).  Does  disability
       insurance  receipt  discourage  work?  Using  examiner  assignment  to
       estimate causal effects of SSDI receipt. <span class='ecti-1200'>American Economic Review</span>,
       <span class='ecti-1200'>103</span>(5), 1797–1829. <a href='https://doi.org/10.1257/aer.103.5.1797'>https://doi.org/10.1257/aer.103.5.1797</a>
       </p></dd><dt class='thebibliography' id='X0-maia2024rsp'>
</dt><dd class='thebibliography' id='bib-62'>
                                                                          

                                                                          
       <!-- l. 646 --><p class='noindent'><a id='cite.0@maia2024rsp'></a>Maia,  L. R.,  et  al.  (2024).  Fiscal  austerity  and  municipal  health
       spending: An analysis of Brazilian municipalities. <span class='ecti-1200'>Revista de Saúde
       </span><span class='ecti-1200'>Pública</span>,  <span class='ecti-1200'>58</span>,  42.  <a href='https://doi.org/10.11606/s1518-8787.2024058005593'>https : / / doi . org / 10 . 11606 / s1518 - 8787 .
       2024058005593</a>
       </p></dd><dt class='thebibliography' id='X0-mcguire2000hhe'>
</dt><dd class='thebibliography' id='bib-63'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@mcguire2000hhe'></a>McGuire, T. G. (2000). Physician agency. In A. J. Culyer &amp; J. P.
       Newhouse  (Eds.),  <span class='ecti-1200'>Handbook  of  health  economics  </span>(pp. 461–536).
       Elsevier. <a href='https://doi.org/10.1016/S1574-0064(00)80168-7'>https://doi.org/10.1016/S1574-0064(00)80168-7</a>
       </p></dd><dt class='thebibliography' id='X0-datasus_sih'>
</dt><dd class='thebibliography' id='bib-64'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@datasus_sih'></a>Ministério   da   Saúde.   (2024a).   Sistema   de   informações
       hospitalares do SUS (SIH/SUS).
       </p></dd><dt class='thebibliography' id='X0-datasus_sim'>
</dt><dd class='thebibliography' id='bib-65'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@datasus_sim'></a>Ministério  da  Saúde.  (2024b).  Sistema  de  informações  sobre
       mortalidade (SIM).
       </p></dd><dt class='thebibliography' id='X0-datasus_sinasc'>
</dt><dd class='thebibliography' id='bib-66'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@datasus_sinasc'></a>Ministério  da  Saúde.  (2024c).  Sistema  de  informações  sobre
       nascidos vivos (SINASC).
       </p></dd><dt class='thebibliography' id='X0-siops'>
</dt><dd class='thebibliography' id='bib-67'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@siops'></a>Ministério  da  Saúde.  (2024d).  Sistema  de  informações  sobre
       orçamentos públicos em saúde (SIOPS).
                                                                          

                                                                          
       </p></dd><dt class='thebibliography' id='X0-cadunico'>
</dt><dd class='thebibliography' id='bib-68'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@cadunico'></a>Ministério  do  Desenvolvimento  e  Assistência  Social.  (2024).
       Cadastro único para programas sociais do governo federal.
       </p></dd><dt class='thebibliography' id='X0-rais'>
</dt><dd class='thebibliography' id='bib-69'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@rais'></a>Ministério  do  Trabalho  e  Emprego.  (2024).  Relação  anual  de
       informações sociais (RAIS).
       </p></dd><dt class='thebibliography' id='X0-morenoserra2015jde'>
</dt><dd class='thebibliography' id='bib-70'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@morenoserra2015jde'></a>Moreno-Serra, R., &amp; Smith, P. C. (2015). Broader health coverage is
       good for the nation’s health: Evidence from country level panel data.
       <span class='ecti-1200'>Journal of the Royal Statistical Society: Series A</span>, <span class='ecti-1200'>178</span>(1), 101–124. <a href='https://doi.org/10.1111/rssa.12048'>https://doi.org/10.1111/rssa.12048</a>
       </p></dd><dt class='thebibliography' id='X0-oates1999jel'>
</dt><dd class='thebibliography' id='bib-71'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@oates1999jel'></a>Oates,  W. E.  (1999).  An  essay  on  fiscal  federalism.  <span class='ecti-1200'>Journal  of
       </span><span class='ecti-1200'>Economic Literature</span>, <span class='ecti-1200'>37</span>(3), 1120–1149. <a href='https://doi.org/10.1257/jel.37.3.1120'>https://doi.org/10.1257/
       jel.37.3.1120</a>
       </p></dd><dt class='thebibliography' id='X0-oliveira2025lancetamericas'>
</dt><dd class='thebibliography' id='bib-72'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@oliveira2025lancetamericas'></a>Oliveira, S. C. P., et al. (2025). The high cost of the legal route in
       public health: Pharmaceutical spending attributable to litigation in
       Campinas, Brazil. <span class='ecti-1200'>The Lancet Regional Health – Americas</span>. <a href='https://doi.org/10.1016/j.lana.2024.100839'>https:
       //doi.org/10.1016/j.lana.2024.100839</a>
                                                                          

                                                                          
       </p></dd><dt class='thebibliography' id='X0-oliveira2020rsp'>
</dt><dd class='thebibliography' id='bib-73'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@oliveira2020rsp'></a>Oliveira,   Y. M. C.,   Braga,   B. S. A.,   Melo,   A. C.,   Pereira,
       J. A. D. B.,  Cherchiglia,  M. L.,  &amp;  Andrade,  E. I. G.  (2020).
       Judicialização de medicamentos: Efetividade de direitos ou ruptura
       na equidade? <span class='ecti-1200'>Revista de Saúde Pública</span>, <span class='ecti-1200'>54</span>, 130. <a href='https://doi.org/10.11606/s1518-8787.2020054002192'>https://doi.org/
       10.11606/s1518-8787.2020054002192</a>
       </p></dd><dt class='thebibliography' id='X0-paim2011lancet'>
</dt><dd class='thebibliography' id='bib-74'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@paim2011lancet'></a>Paim, J., Travassos, C., Almeida, C., Bahia, L., &amp; Macinko, J. (2011).
       The Brazilian health system: History, advances, and challenges. <span class='ecti-1200'>The
       </span><span class='ecti-1200'>Lancet</span>, <span class='ecti-1200'>377</span>(9779), 1778–1797. <a href='https://doi.org/10.1016/S0140-6736(11)60054-8'>https://doi.org/10.1016/S0140-
       6736(11)60054-8</a>
       </p></dd><dt class='thebibliography' id='X0-pepe2010csp'>
</dt><dd class='thebibliography' id='bib-75'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@pepe2010csp'></a>Pepe, V. L. E., de Castro Figueiredo, T., Siqueira Osorio-de-Castro,
       C. G.,   Castanheira   Nascimento,   T.,   &amp;   Ventura,   M.   (2010).
       Characterization of lawsuits for the supply of “essential”  medicines
       in the state of Rio de Janeiro, Brazil. <span class='ecti-1200'>Cadernos de Saúde Pública</span>,
       <span class='ecti-1200'>26</span>(3),  461–471.  <a href='https://doi.org/10.1590/S0102-311X2010000300004'>https : / / doi . org / 10 . 1590 / S0102 -
       311X2010000300004</a>
       </p></dd><dt class='thebibliography' id='X0-piola2012ipea'>
</dt><dd class='thebibliography' id='bib-76'>
                                                                          

                                                                          
       <!-- l. 646 --><p class='noindent'><a id='cite.0@piola2012ipea'></a>Piola,  S. F.,  Paiva,  A. B. d.,  Sá,  E. B. d.,  &amp;  Servo,  L. M. S.
       (2013). <span class='ecti-1200'>Financiamento público da saúde: Uma história à </span><span class='ecti-1200'>procura
       </span><span class='ecti-1200'>de rumo </span>[Texto para Discussão 1846]. IPEA.
       </p></dd><dt class='thebibliography' id='X0-rasella2018plosmed'>
</dt><dd class='thebibliography' id='bib-77'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@rasella2018plosmed'></a>Rasella,  D.,  Basu,  S.,  Hone,  T.,  Paes-Sousa,  R.,  Océ,  M. S.,  &amp;
       Millett,  C.  (2018).  Child  morbidity  and  mortality  associated  with
       alternative  policy  responses  to  the  economic  crisis  in  Brazil:  A
       nationwide microsimulation study. <span class='ecti-1200'>PLOS Medicine</span>, <span class='ecti-1200'>15</span>(5), e1002570.
       <a href='https://doi.org/10.1371/journal.pmed.1002570'>https://doi.org/10.1371/journal.pmed.1002570</a>
       </p></dd><dt class='thebibliography' id='X0-rasella2014bmj'>
</dt><dd class='thebibliography' id='bib-78'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@rasella2014bmj'></a>Rasella,  D.,  Hone,  T.,  de  Souza,  L. E.,  Tasca,  R.,  Basu,  S.,  &amp;
       Millett, C. (2014). Impact of primary health care on mortality from
       heart and cerebrovascular diseases in Brazil: A nationwide analysis of
       longitudinal data. <span class='ecti-1200'>BMJ</span>, <span class='ecti-1200'>349</span>, g4014. <a href='https://doi.org/10.1136/bmj.g4014'>https://doi.org/10.1136/bmj.
       g4014</a>
       </p></dd><dt class='thebibliography' id='X0-rochasoares2010he'>
</dt><dd class='thebibliography' id='bib-79'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@rochasoares2010he'></a>Rocha,  R.,  &amp;  Soares,  R. R.  (2010).  Evaluating  the  impact  of
       community-based health interventions: Evidence from Brazil’s Family
       Health Program. <span class='ecti-1200'>Health Economics</span>, <span class='ecti-1200'>19</span>(S1), 126–158. <a href='https://doi.org/10.1002/hec.1607'>https://doi.
       org/10.1002/hec.1607</a>
       </p></dd><dt class='thebibliography' id='X0-shavell1982jls'>
</dt><dd class='thebibliography' id='bib-80'>
                                                                          

                                                                          
       <!-- l. 646 --><p class='noindent'><a id='cite.0@shavell1982jls'></a>Shavell, S. (1982). The social versus the private incentive to bring suit
       in a costly legal system. <span class='ecti-1200'>Journal of Legal Studies</span>, <span class='ecti-1200'>11</span>(2), 333–339. <a href='https://doi.org/10.1086/467535'>https://doi.org/10.1086/467535</a>
       </p></dd><dt class='thebibliography' id='X0-soaresdepra2012physis'>
</dt><dd class='thebibliography' id='bib-81'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@soaresdepra2012physis'></a>Soares,   J. C. R. d. S.,   &amp;   Deprá,   A. S.   (2012).   Ligações
       perigosas: Indústria farmacêutica, associações de pacientes e as
       batalhas  judiciais  por  acesso  a  medicamentos.  <span class='ecti-1200'>Physis:  Revista  de
       </span><span class='ecti-1200'>Saúde Coletiva</span>, <span class='ecti-1200'>22</span>(1), 311–329. <a href='https://doi.org/10.1590/S0103-73312012000100017'>https://doi.org/10.1590/S0103-
       73312012000100017</a>
       </p></dd><dt class='thebibliography' id='X0-tamachiro2022csp'>
</dt><dd class='thebibliography' id='bib-82'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@tamachiro2022csp'></a>Tamachiro,  N. C.,  Gonçalves,  R. F.,  Simone,  L. d.,  &amp;  Aguiar,
       P. M.  (2022).  Pharmaceutical  industry  interference  in  the  process
       of drug incorporation by CONITEC. <span class='ecti-1200'>Cadernos de Saúde Pública</span>,
       <span class='ecti-1200'>38</span>(8), e00293221. <a href='https://doi.org/10.1590/0102-311XEN293221'>https://doi.org/10.1590/0102-311XEN293221</a>
       </p></dd><dt class='thebibliography' id='X0-tcu2017'>
</dt><dd class='thebibliography' id='bib-83'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@tcu2017'></a>Tribunal de Contas da União. (2017). <span class='ecti-1200'>Aumentam os gastos públicos
       </span><span class='ecti-1200'>com judicialização da saúde </span>(Audit Report). TCU.
       </p></dd><dt class='thebibliography' id='X0-tcesp_audesp'>
</dt><dd class='thebibliography' id='bib-84'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@tcesp_audesp'></a>Tribunal  de  Contas  do  Estado  de  São  Paulo.  (2024).  Portal  da
       transparência municipal.
                                                                          

                                                                          
       </p></dd><dt class='thebibliography' id='X0-tjsp_esaj'>
</dt><dd class='thebibliography' id='bib-85'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@tjsp_esaj'></a>Tribunal  de  Justiça  do  Estado  de  São  Paulo.  (2024).  E-SAJ:
       Sistema  de  automação  da  justiça  [Consulta  de  Julgados  and
       Diário de Justiça Eletrônico].
       </p></dd><dt class='thebibliography' id='X0-vieira2020hhr'>
</dt><dd class='thebibliography' id='bib-86'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@vieira2020hhr'></a>Vieira,  F. S.  (2020).  Right-to-medicines  litigation  and  universal
       health coverage: Institutional determinants of the judicialization of
       health in Brazil. <span class='ecti-1200'>Health and Human Rights</span>, <span class='ecti-1200'>22</span>(1), 119–131.
       </p></dd><dt class='thebibliography' id='X0-wang2015hepl'>
</dt><dd class='thebibliography' id='bib-87'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@wang2015hepl'></a>Wang, D. W. L. (2015). Courts and health care rationing: The case of
       the Brazilian Federal Supreme Court. <span class='ecti-1200'>Health Economics, Policy and
       </span><span class='ecti-1200'>Law</span>, <span class='ecti-1200'>10</span>(4), 389–407. <a href='https://doi.org/10.1017/S1744133115000067'>https://doi.org/10.1017/S1744133115000067</a>
       </p></dd><dt class='thebibliography' id='X0-wangferraz2013sur'>
</dt><dd class='thebibliography' id='bib-88'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@wangferraz2013sur'></a>Wang, D. W. L., &amp; Ferraz, O. L. M. (2013). Reaching out to the
       needy? access to justice and public attorneys’ role in right-to-health
       litigation in the city of São Paulo. <span class='ecti-1200'>SUR – International Journal on
       </span><span class='ecti-1200'>Human Rights</span>, <span class='ecti-1200'>10</span>(18), 159–179.
       </p></dd><dt class='thebibliography' id='X0-wang2014rap'>
</dt><dd class='thebibliography' id='bib-89'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@wang2014rap'></a>Wang,  D. W. L.,  Vasconcelos,  N. P. d.,  Oliveira,  V. E. d.,  &amp;
       Terrazas, F. V. (2014). Os impactos da judicialização da saúde
                                                                          

                                                                          
       no  município  de  São  Paulo:  Gasto  público  e  organização
       federativa. <span class='ecti-1200'>Revista de Administração Pública</span>, <span class='ecti-1200'>48</span>(5), 1191–1206. <a href='https://doi.org/10.1590/0034-76121666'>https://doi.org/10.1590/0034-76121666</a>
       </p></dd><dt class='thebibliography' id='X0-yamin2010hastings'>
</dt><dd class='thebibliography' id='bib-90'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@yamin2010hastings'></a>Yamin,  A. E.  (2010).  Judicial  protection  of  the  right  to  health
       in Colombia. <span class='ecti-1200'>Hastings International and Comparative Law Review</span>,
       <span class='ecti-1200'>33</span>(1).
       </p></dd><dt class='thebibliography' id='X0-yamingloppen2011'>
</dt><dd class='thebibliography' id='bib-91'>
       <!-- l. 646 --><p class='noindent'><a id='cite.0@yamingloppen2011'></a>Yamin, A. E., &amp; Gloppen, S. (Eds.). (2011). <span class='ecti-1200'>Litigating health rights:
       </span><span class='ecti-1200'>Can courts bring more justice to health? </span>Harvard University Press.</p></dd></dl>
<!-- l. 650 --><p class='noindent'>
</p>
   <h3 class='sectionHead' id='detailed-jurisprudence'><span class='titlemark'>A   </span> <a id='x1-60000A'></a>Detailed Jurisprudence</h3>
<!-- l. 653 --><p class='noindent'>This appendix provides additional detail on the key judicial rulings discussed in
Section <a href='#institutional-background'>3<!-- tex4ht:ref: sec:background  --></a>.
</p>
<!-- l. 655 --><p class='noindent'><span class='paragraphHead' id='sta-'><a id='x1-61000A'></a><span class='ecbx-1200'>STA 175 (2009–2010).</span></span>
   The first major institutional response came in 2009–2010, when the STF
convened a public hearing on health (Audiência Pública No. 4) and
                                                                          

                                                                          
subsequently issued its decision in STA 175. The ruling established parameters for
judicial decision-making—distinguishing cases where existing SUS policy is not
being implemented from cases requesting treatments outside the standard
benefit package, and discouraging orders for experimental treatments.
<span class='ecti-1200'>[Identification] </span>If binding, STA 175 would reduce judge discretion for
off-formulary requests; the evidence below suggests limited compliance in our
period.
</p>
<!-- l. 659 --><p class='noindent'><span class='paragraphHead' id='natjus-'><a id='x1-62000A'></a><span class='ecbx-1200'>NAT-JUS (2016).</span></span>
   CNJ Resolution 238 created NAT-JUS (Núcleos de Apoio Técnico do
Judiciário), technical advisory bodies composed of physicians and pharmacists
that provide evidence-based opinions to assist judges in health cases. The
electronic platform e-NatJus, launched in 2017, gives judges access to
standardized technical assessments and CONITEC reports, reducing reliance on
plaintiff-submitted medical prescriptions alone. <span class='ecti-1200'>[First stage] </span>NAT-JUS
availability could reduce judge-level variation in granting rates; we test
whether the instrument’s first stage weakens in districts with NAT-JUS
infrastructure.
</p>
<!-- l. 663 --><p class='noindent'><span class='paragraphHead' id='tema-'><a id='x1-63000A'></a><span class='ecbx-1200'>Tema 106 (2018).</span></span>
   The STJ’s ruling on Tema 106 (REsp 1,657,156) established three cumulative
                                                                          

                                                                          
requirements for ordering medicines not incorporated into SUS: (i) a detailed
medical report demonstrating inefficacy of SUS alternatives, (ii) proof of the
patient’s financial incapacity, and (iii) existing ANVISA registration.
<span class='ecti-1200'>[Composition] </span>If enforced, Tema 106 raises the bar for off-formulary orders,
potentially changing the composition of marginal cases in our sample from 2018
onward.
</p>
<!-- l. 667 --><p class='noindent'><span class='paragraphHead' id='tema-1'><a id='x1-64000A'></a><span class='ecbx-1200'>Tema 500 (2019).</span></span>
   The STF’s ruling on Tema 500 (RE 657,718) held that drugs without ANVISA
registration generally cannot be judicially ordered, with narrow exceptions for
unreasonable regulatory delay. <span class='ecti-1200'>[Composition] </span>If binding, Tema 500 eliminates the
highest-risk judicial orders (unregistered drugs); we test for compositional shifts in
judicial spending around 2019.
</p>
<!-- l. 671 --><p class='noindent'><span class='paragraphHead' id='evidence-on-compliance-with-judicial-standards'><a id='x1-65000A'></a><span class='ecbx-1200'>Evidence on compliance with judicial standards.</span></span>
   Despite these formal constraints, there is little evidence that they substantially
changed judicial behavior. A 2019 study commissioned by the CNJ, based on a
nationally representative sample of first-instance health decisions, found that
fewer than 6 percent explicitly cited CONITEC reports, RENAME lists, or other
technical standards when ruling on medication requests (<a id='x1-65001'></a>CNJ/INSPER, <a href='#cite.0@cnjinsper2019'>2019</a>).
Separately, data from state courts with NAT-JUS infrastructure reveal that over
                                                                          

                                                                          
80 percent of cases flagged as “urgent” by plaintiffs do not meet clinical urgency
criteria upon technical review, yet the consultation process is frequently bypassed
(<a id='x1-65002'></a>Conselho Nacional de Justiça &amp; Programa das Nações Unidas para
o Desenvolvimento, <a href='#cite.0@cnjpnud2025'>2025</a>). The volume of “supply of medicines” cases
dipped by only 4 percent between 2017 and 2018, when Tema 106 took
effect, and overall health litigation continued to accelerate through the
2020s.
</p>
<!-- l. 674 --><p class='noindent'><span class='paragraphHead' id='-reforms'><a id='x1-66000A'></a><span class='ecbx-1200'>2024 reforms.</span></span>
   The STF’s 2024 decisions on Temas 1,234 and 6 consolidated the criteria for
non-incorporated drugs, established cost thresholds directing cases above 210
minimum salaries to the federal courts, and introduced a federal reimbursement
mechanism. Súmulas Vinculantes 60 and 61, also issued in 2024, imposed a
binding administrative exhaustion requirement: patients must first seek the
treatment through SUS’s administrative channels before filing suit. Early evidence
suggests modest effects: SUS-related lawsuits declined approximately 7 percent in
the first half of 2025, but grant rates for preliminary injunctions remain above 73
percent (<a id='x1-66001'></a>Conselho Nacional de Justiça &amp; Programa das Nações Unidas para o
Desenvolvimento, <a href='#cite.0@cnjpnud2025'>2025</a>). <span class='ecti-1200'>[Sample boundary] </span>Our main analysis focuses on the
pre-reform period; the 2024 changes define a natural boundary for our
sample.
                                                                          

                                                                          
</p><!-- l. 679 --><p class='noindent'>
</p>
   <h3 class='sectionHead' id='data-construction-details'><span class='titlemark'>B   </span> <a id='x1-67000B'></a>Data Construction Details</h3>
<!-- l. 682 --><p class='noindent'>This appendix describes the construction of the litigation, spending, and
individual-linkage datasets used in the analysis.
</p><!-- l. 684 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='tpu-code-curation'><span class='titlemark'>B.1   </span> <a id='x1-68000B.1'></a>TPU Code Curation</h4>
<!-- l. 687 --><p class='noindent'>We identify health-related cases in the DataJud national case repository
using Tabela Processual Unificada (TPU) subject codes. The procedure
is:
      </p><ol class='enumerate1'>
<li class='enumerate' id='x1-68002x1'>Start  from  the  “Direito  Administrativo  e  Outras  Matérias  de
      Direito Público” branch, “Saúde” subtree (codes 10064, 10069, and
      descendants).
      </li>
<li class='enumerate' id='x1-68004x2'>Include:  “Fornecimento  de  Medicamentos”  (supply  of  medicines),
      “Tratamento Médico-Hospitalar e/ou Fornecimento de Medicamentos”
                                                                          

                                                                          
      (medical-hospital  treatment  and/or  supply  of  medicines),  “Leitos”
      (hospital beds), “Unidade de Tratamento Intensivo (UTI)” (ICU), and
      related subcategories.
      </li>
<li class='enumerate' id='x1-68006x3'>Exclude:  “Ressarcimento  ao  SUS”   (reimbursement  to  SUS)  and
      “Contratos e Licitações” (contracts and procurement), which involve
      disputes between government and providers rather than patient claims.</li></ol>
<!-- l. 695 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='threesource-crossvalidation'><span class='titlemark'>B.2   </span> <a id='x1-69000B.2'></a>Three-Source Cross-Validation</h4>
<!-- l. 698 --><p class='noindent'>Our litigation data draw on three complementary sources:
      </p><ol class='enumerate1'>
<li class='enumerate' id='x1-69002x1'><span class='ecbx-1200'>DataJud </span>(2020–present): structured metadata—case number, court,
      filing date, subject codes, parties, judge—for all cases in the Brazilian
      judiciary.
      </li>
                                                                          

                                                                          
<li class='enumerate' id='x1-69004x2'><span class='ecbx-1200'>Diário de Justiça Eletrônico </span>(2007–present): official gazette of
      TJSP and TRF3, publishing decisions, orders, and procedural events.
      </li>
<li class='enumerate' id='x1-69006x3'><span class='ecbx-1200'>Consulta de Julgados </span>(2014–present, TJSP only): full-text decisions
      from which we extract treatment requested, diagnosis, and grant/deny
      outcomes.</li></ol>
<!-- l. 704 --><p class='noindent'>We merge across sources using the unique CNJ-format case number. When sources
overlap and disagree, we apply the following precedence rule: (i) for judge identity
and filing date, DataJud takes precedence as the authoritative structured registry;
(ii) for decision outcomes (grant/deny, treatment details), Consulta de Julgados
takes precedence because it provides the full-text decision; (iii) for procedural
events (hearing dates, interim orders), the gazette takes precedence as the official
record of publication. Conflicts are rare (fewer than 2 percent of overlapping
cases) and concentrated in filing-date discrepancies of one to two business
days.
</p><!-- l. 708 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='judicialcompliance-descriptors'><span class='titlemark'>B.3   </span> <a id='x1-70000B.3'></a>Judicial-Compliance Descriptors</h4>
<!-- l. 711 --><p class='noindent'>We identify court-mandated expenditures in the TCE-SP budget data by
                                                                          

                                                                          
searching the transaction history (<span class='ecti-1200'>histórico</span>) field for the following descriptors,
applied case-insensitively: </p>
      <ul class='itemize1'>
      <li class='itemize'><span class='ecti-1200'>determinação judicial </span>(judicial determination)
      </li>
      <li class='itemize'><span class='ecti-1200'>tutela antecipada </span>(preliminary injunction)
      </li>
      <li class='itemize'><span class='ecti-1200'>cumprimento de sentença </span>(compliance with judgment)
      </li>
      <li class='itemize'><span class='ecti-1200'>ação judicial </span>(judicial action / lawsuit)
      </li>
      <li class='itemize'><span class='ecti-1200'>mandado de segurança </span>(writ of mandamus)
      </li>
      <li class='itemize'><span class='ecti-1200'>ordem judicial </span>(court order)
                                                                          

                                                                          
      </li>
      <li class='itemize'><span class='ecti-1200'>decisão judicial </span>(judicial decision)
      </li>
      <li class='itemize'><span class='ecti-1200'>processo judicial </span>(judicial proceeding)
      </li>
      <li class='itemize'><span class='ecti-1200'>liminar </span>(injunction)
      </li>
      <li class='itemize'><span class='ecti-1200'>obrigação de fazer </span>(obligation to act)
      </li>
      <li class='itemize'><span class='ecti-1200'>tutela de urgência </span>(emergency relief)</li></ul>
<!-- l. 725 --><p class='noindent'>Some descriptors—particularly <span class='ecti-1200'>ação judicial </span>and <span class='ecti-1200'>processo judicial</span>—are broad
enough to match non-compliance contexts (e.g., expenditures related to lawsuits
<span class='ecti-1200'>filed by </span>the municipality). To guard against false positives, we restrict
matches to expenditures classified under the Health function and exclude
entries where the municipality appears as the plaintiff rather than the
defendant.
                                                                          

                                                                          
</p><!-- l. 727 --><p class='indent'>   We validate the text-based identification in two ways: (i) comparing total
tagged judicial spending per municipality against spending estimates derived
independently from court records (case-level treatment costs), and (ii) manual
audit of a random sample of 500 tagged transactions, with the audit explicitly
checking whether broad-string matches (e.g., <span class='ecti-1200'>ação judicial</span>) correctly identify
compliance spending.
</p><!-- l. 729 --><p class='noindent'>
</p>
   <h4 class='subsectionHead' id='namelinkage-procedure'><span class='titlemark'>B.4   </span> <a id='x1-71000B.4'></a>Name-Linkage Procedure</h4>
<!-- l. 732 --><p class='noindent'><span class='paragraphHead' id='baseline-procedure'><a id='x1-72000B.4'></a><span class='ecbx-1200'>Baseline procedure.</span></span>
   We link individuals appearing in health lawsuits to RAIS and CadÚnico using
unique full names (first name, all middle names, last name). To minimize false
matches, we restrict to verified unique names: individuals whose full name
appears exactly once in both the litigation records and the target registry
within the relevant state and year. We exclude names appearing more than
once in either source. This conservative approach sacrifices coverage for
precision.
</p>
<!-- l. 735 --><p class='noindent'><span class='paragraphHead' id='sensitivity-variants'><a id='x1-73000B.4'></a><span class='ecbx-1200'>Sensitivity variants.</span></span>
                                                                          

                                                                          
   We assess robustness to two alternative linkage definitions: (i) fuzzy name
matching using Jaro-Winkler similarity above 0.95, which accommodates minor
spelling variations and accent differences; and (ii) exact name matching
augmented with date of birth where available, which permits matching of more
common names at the cost of restricting to cases where birth dates are
recorded. We report match rates and outcome estimates under all three
definitions.
</p>
<!-- l. 738 --><p class='noindent'><span class='paragraphHead' id='selection-and-representativeness'><a id='x1-74000B.4'></a><span class='ecbx-1200'>Selection and representativeness.</span></span>
   The unique-name restriction creates selection: matched litigants are likely to
have rarer names, which may correlate with socioeconomic status, ethnicity,
or region of origin. To assess representativeness, we compare observable
characteristics (case type, court, filing year, grant rate, municipality of origin)
between matched and unmatched litigants. We also compare the distribution of
municipality-level covariates for municipalities with high versus low match rates.
If matched litigants are systematically different, we report how this affects the
interpretation of the distributional analysis.
</p><!-- l. 742 --><p class='noindent'>
</p>
   <h3 class='sectionHead' id='supplyside-case-studies'><span class='titlemark'>C   </span> <a id='x1-75000C'></a>Supply-Side Case Studies</h3>
<!-- l. 745 --><p class='noindent'>This appendix documents supply-side mechanisms discussed in Section <a href='#supplyside-drivers-lawyer-concentration-and-pharmaceutical-networks'>8.4<!-- tex4ht:ref: sec:supplyside  --></a>. Each
                                                                          

                                                                          
case study identifies the mechanism, the key evidence, and the testable
implication for our empirical design.
</p>
<!-- l. 747 --><p class='noindent'><span class='paragraphHead' id='referral-networks-and-intermediary-organizations'><a id='x1-76000C'></a><span class='ecbx-1200'>Referral networks and intermediary organizations.</span></span>
   <span class='ecti-1200'>Mechanism: </span>Physicians prescribe specific brand-name drugs—sometimes under
commercial arrangements with manufacturers—and refer patients to specialized
law firms that file standardized petitions. Patient associations, often funded
by pharmaceutical companies, recruit litigants and connect them with
legal representation (<a id='x1-76001'></a>Soares &amp; Deprá, <a href='#cite.0@soaresdepra2012physis'>2012</a>). <span class='ecti-1200'>Evidence: </span><a id='x1-76002'></a>Machado et al.
(<a href='#cite.0@machado2011rsp'>2011</a>) document that in Minas Gerais (1999–2009), one physician from a
single private law office accounted for 44 percent of prescriptions in 117
judicial actions for a specific biologic drug. Concentration was highest for
expensive medications not yet incorporated into SUS. <span class='ecti-1200'>Testable implication: </span>If
supply-side networks generate the marginal cases, high-volume-lawyer
cases should show weaker health returns than low-volume or Defensoria
cases.
</p>
<!-- l. 752 --><p class='noindent'><span class='paragraphHead' id='opera-cao-garra-rufa-'><a id='x1-77000C'></a><span class='ecbx-1200'>Operação Garra Rufa (2008).</span></span>
   <span class='ecti-1200'>Mechanism: </span>Organized fraud networks fabricate lawsuits using cooperating
physicians, patient associations, and specialized attorneys. <span class='ecti-1200'>Evidence: </span>A police
investigation uncovered a network involving three pharmaceutical laboratories, a
                                                                          

                                                                          
patient association, doctors, and lawyers that had obtained R$63 million from the
state of São Paulo through fabricated health lawsuits—many filed without the
knowledge of the nominal plaintiffs. <span class='ecti-1200'>Testable implication: </span>Cases routed
through a small number of attorneys are more likely to be supply-driven; our
lawyer-concentration split captures this margin.
</p>
<!-- l. 757 --><p class='noindent'><span class='paragraphHead' id='eculizumab-and-opera-cao-calice-de-higia'><a id='x1-78000C'></a><span class='ecbx-1200'>Eculizumab and Operação Cálice de Hígia.</span></span>
   <span class='ecti-1200'>Mechanism: </span>Geographic forum shopping and diagnostic fraud enable
concentrated litigation for a single high-cost drug. <span class='ecti-1200'>Evidence: </span>Eculizumab cost SUS
R$2.44 billion over eleven years. A single law firm filed approximately 70 percent
of 514 federal actions, with 73 percent originating in the Federal District rather
than where patients resided; roughly half of patients lacked confirmed
diagnostic evidence (<a id='x1-78001'></a>Folha de S.Paulo, <a href='#cite.0@folha2020eculizumab'>2020</a>). After police intervention in
2017, judicial purchases fell by 49.5 percent and the drug’s price dropped
35 percent after ANVISA registration. <span class='ecti-1200'>Testable implication: </span>Single-firm
dominance is captured by our lawyer-concentration split; we document
geographic concentration descriptively as suggestive evidence of supply-side
organization.
</p>
<!-- l. 762 --><p class='noindent'><span class='paragraphHead' id='strategic-interaction-with-conitec'><a id='x1-79000C'></a><span class='ecbx-1200'>Strategic interaction with CONITEC.</span></span>
   <span class='ecti-1200'>Mechanism: </span>Manufacturers with weak clinical evidence bypass the health
                                                                          

                                                                          
technology assessment process, preferring courts where grant rates exceed 80
percent. <span class='ecti-1200'>Evidence: </span>Among 514 incorporation requests to CONITEC (2012–2020),
pharmaceutical companies submitted 37 percent of requests and contributed over
70 percent of public consultation responses (<a id='x1-79001'></a>Tamachiro et al., <a href='#cite.0@tamachiro2022csp'>2022</a>). When
manufacturers anticipate rejection, some deliberately avoid requesting CONITEC
evaluation; the absence of a formal negative recommendation facilitates the
judicial route. <span class='ecti-1200'>Testable implication: </span>We document descriptively whether drugs
that bypassed CONITEC are overrepresented among court-mandated purchases;
if so, this is consistent with supply-driven cases having weaker clinical
justification.
</p>
</div>
</main>

<footer>
  Generated by <code>bash build.sh site</code>
</footer>

</body>
</html>
